Team:Freiburg Bioware/NoteBook/Labjournal/Cellculture

From 2010.igem.org

(Difference between revisions)
(→19.6 Seeding AAV293 for second transfection according to standard protocol)
 
(387 intermediate revisions not shown)
Line 1: Line 1:
{{:Team:Freiburg_Bioware/css}}
{{:Team:Freiburg_Bioware/css}}
-
{{:Team:Freiburg_Bioware/SubNoteBook}}
 
{{:Team:Freiburg_Bioware/Head}}
{{:Team:Freiburg_Bioware/Head}}
 +
{{:Team:Freiburg_Bioware/menu_notebook}}
<!-- Freiburg_bioware -->
<!-- Freiburg_bioware -->
Line 20: Line 20:
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/September">September part 1 (labday 107 - 123)</a></li>
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/September">September part 1 (labday 107 - 123)</a></li>
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/September2">September part 2 (labday 124 - 135)</a></li>
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/September2">September part 2 (labday 124 - 135)</a></li>
-
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/October">October part 1 (labday 136 - 145 )</a></li>
+
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/October">October part 1 (labday 136 - 149 )</a></li>
-
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/October2">October part 2 (labday 146 - 155 )</a></li>
+
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/October2">October part 2 (labday 150 - 166 )</a></li>
-
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/October3">October part 3 (labday 156 - 166 )</a></li>
+
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/November">November  (labday 167 - 170 )</a></li>
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/November">November  (labday 167 - 170 )</a></li>
-
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/Cellculture">Cellculture </a></li>
+
<li><a href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/Cellculture">Cellculture</a></li>
</ul>
</ul>
</div>
</div>
Line 55: Line 54:
<br />
<br />
<b>The plan</b><br />
<b>The plan</b><br />
-
AAV 293 and HT1080 Cells have been splitted and plated out on 10 cm dishes for transfektion.
+
 
-
The Cells were accounted by using the Neubauer-Meteringchamber.
+
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
-
After harvesting by following the standard protocol the pallet have been resuspendiated in 15ml of DTT medium.
+
<tr>
-
2,5µl of this cell suspension have been mixed with 47.5µl of trypan blue.
+
<th width="100">Days</th>
 +
<th width="100">14.6</th>
 +
<th width="100">15.6</th>
 +
<th width="100">16.6</th>
 +
<th width="100">17.6</th>
 +
<th width="100">18.6</th>
 +
<th width="100">19.6</th>
 +
<th width="100">20.6</th>
 +
<th width="100">21.6</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>Fluorescence microscopy</td>
 +
</tr>
 +
</table>
 +
AAV 293 and HT1080 Cells have been splitted and plated out on 10 cm dishes for transfektion. After harvesting the cells according to the standard protocol the cell-pellets were resuspendiated in 15ml of DYT medium.
 +
2,5µl of this cell suspension have been mixed with 47.5µl of trypan blue and the cells were counted by using the Neubauer-Meteringchamber.
We counted 12,5x 10^6 cells/ml for the AAV293 cell line and 10x10^6 cells /ml for the HT1080 cell line.
We counted 12,5x 10^6 cells/ml for the AAV293 cell line and 10x10^6 cells /ml for the HT1080 cell line.
-
The AAV 293 cells have been plated out on four dishes with 250µl of the cell suspension, on one plated with 1ml and on another dish
+
1ml and 1,5 ml of the AAV 293 cells have been seeded on four dishes with 250µl of the cell suspension.
-
with 1.5ml.
+
Note that that the date is wrong on the plates and the flasks! Cells have been already plated out on the 14th. of June.
-
note that that the date is wrong on the plates and the flasks! Cells have been already plated out on the 14th. of June.
+
-
We also seated two flasks one for each cell line. Therefor we used 1ml of the HT1080 cell suspension and two ml of the the AAV293 cells.
+
We also seated two flasks one for each cell line. Therefor we used 1ml of the HT1080 cell suspension and 2ml of the the AAV293 cells.
<br />
<br />
1)  
1)  
Line 90: Line 111:
Adrian tried to examine the precipation of the CaCl2+ DNA Clusters. We have to optimize the pH of our 2xHBS at the moment it is 11.12.
Adrian tried to examine the precipation of the CaCl2+ DNA Clusters. We have to optimize the pH of our 2xHBS at the moment it is 11.12.
<br />
<br />
-
The viral stocks are harvested according to standard protocol.
+
The viral stocks were harvested according to standard protocol.
<br>
<br>
<b>The results</b><br />
<b>The results</b><br />
Line 106: Line 127:
<br />
<br />
<b>The motivation</b><br />
<b>The motivation</b><br />
-
We want to repeat the last transfection to exclude faults in practical
+
We want to repeat the last transfection and obtain a vsibly higher GOI (mVenus) expression.
<br />
<br />
<b>The plan</b><br />
<b>The plan</b><br />
-
Six transfections were performed according to the standart protocol: [[Media:Freiburg10_Transfection_protocoll.pdf]]<br>
+
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">19.6</th>
 +
<th width="100">20.6</th>
 +
<th width="100">20.6</th>
 +
<th width="100">21.6</th>
 +
<th width="100">22.6</th>
 +
<th width="100">23.6</th>
 +
<th width="100">24.6</th>
 +
<th width="100">25.6</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>Fluorescence microscopy</td>
 +
</tr>
 +
</table>
 +
Six transfections were performed according to the standart protocol:<br>
Three 10 cm cellcluture dishes with 293 cells were transfected with 10 µg DNA (3,33 µg each plasmid) and the other three 10 cm cellculture dishes with 30 µg DNA (10 µg DNA each plasmid).
Three 10 cm cellcluture dishes with 293 cells were transfected with 10 µg DNA (3,33 µg each plasmid) and the other three 10 cm cellculture dishes with 30 µg DNA (10 µg DNA each plasmid).
Line 133: Line 178:
The Transduction efficency is still quite low! We have to optimize the stratagene protocol!
The Transduction efficency is still quite low! We have to optimize the stratagene protocol!
-
===<p style="font-size:17px; background-color:#00dd77;">11.8.2010 Transduction of HT1080 with no AAV, AAV without GOI and AAV with 10µg -> FACS</p>===
+
===<p style="font-size:17px; background-color:#00dd77;">30.6 Examination of different Transduction methods</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
We want to check whether the amount of our produced AAV2s has an effect on the transduction rate.
 +
Instead of 500µl, 1000µl of the AAV-stock were pipetted into each well.
 +
<br /><br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">30.6</th>
 +
<th width="100">1.7</th>
 +
<th width="100">2.7</th>
 +
<th width="100">3.7</th>
 +
<th width="100">4.7</th>
 +
<th width="100">5.7</th>
 +
<th width="100">6.7</th>
 +
<th width="100">7.7</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>Fluorescence microscopy</td>
 +
</tr>
 +
</table>
 +
 
 +
1. Plate I(A is up)
 +
{| border="1"
 +
| 3x10^5 cells  || align="right" |3x10^5 cells || align="right" |3x10^5 cells
 +
|-
 +
| 3x10^5 cells  ||  align="right" | 3x10^5 cells||  align="right" | 3x10^5 cells
 +
|-
 +
|}
 +
Transduction:
 +
<br>
 +
 
 +
{| border="1"
 +
| 1000 µl of Viral Stock  DROPPED || align="right" |1000 µl of Viral Stock gently resuspended|| align="right" |1500 µl of Viral Stock rough resuspending
 +
|-
 +
| 1000 µl of Viral Stock  DROPPED ||  align="right" | 1000 µl of Viral Stock gently resuspended||  align="right" | no Transduction
 +
|-
 +
|}
 +
 
 +
<br>
 +
 
 +
<b>The results</b><br />
 +
All cells died probably because we forgot to wash the cells with PBS before adding fresh medium. It was not possible to take pictures because the dead cells were all clumped.
 +
Looks like we should not transduce 3x10^5 cells with 1000 µl (or more) of our viral solution because almost all cells died in all approaches and the medium indicator was yellow.
 +
So we can not say if resuspendig the cells with the viral soultion is a useful alteration of the standard protocol.
 +
<br>
-
<b>The motivation</b>: In the past, the percentage of living cells in FACS was very low (~ 70%) so we want to check if the AAV-induced stress is responsible for cellular death, or the detaching procedure (trypsin and mechanical stress).<br />
 
<br />
<br />
-
<b>The plan</b>
+
 
 +
===<p style="font-size:17px; background-color:#00dd77;">3.7 Seeding AAV293 for transfection with different plasmid amounts and harvesting methods</p>===
<br />
<br />
-
Plate I
+
<b>The motivation</b><br />
 +
We want to check if the amount of plasmids is the reason for the low transduction efficiency. Unfortunately the flow cytometry (FACS) is not available at the moment so the results can only be checked via fuorescence microscopy.
 +
<br /><br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">3.7</th>
 +
<th width="100">4.7</th>
 +
<th width="100">5.7</th>
 +
<th width="100">6.7</th>
 +
<th width="100">7.7</th>
 +
<th width="100">8.7</th>
 +
<th width="100">9.7</th>
 +
<th width="100">10.7</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>Fluorescence microscopy</td>
 +
</tr>
 +
</table>
 +
Transfection with P41 (pAAV_iGEM-MCS_mVenus) was performed according standart protocol.
 +
Two transfections where carried out with 10µg (3,33 µg each plasmid) DNA and the other two with 20µg DNA (6,66 µg each plasmid).<br />
 +
We want to investigate which of the following approaches yields a better transduction efficiency.
 +
*Half of the transfected cells were exposed 3 cycles of thawing and freezing and then centrifuged (15 ml falcon, 2100G). The supernatant was transfered into a new 15 ml falcon and used for transduction.
 +
*The other half was centrifuged at 300 G for 5min . The supernatant was transfered into another 15 ml falcon and the pellet was resuspended with 5 ml of DMEM. The content of these two falcons was also exposed to 3 cycles of thawing and freezing and then used for transduction.
 +
 
 +
* We have got 2 10 cm cellculture dishes with 10µg and 2 dishes with 20µg DNA used for transfection.
 +
 
 +
Approach with standart protocol (one dish with 10 and the other with 20µg Plasmids)(2100 G and 3 cycles of freezing and thawing)
 +
 
 +
Deviations from the standart protocol:
 +
* The cells were centrifuged at 2100 G instead of 10.000 G
 +
* The viruses were harvested after 44 hours
 +
* 3 cycles of freezing and thawing
 +
<br />
 +
* used plasmids: 10µg, 20µg GOI-plasmid (mVenus)
 +
* we have 10µg and 20µg from standart protocol => standard virus
 +
* we have 10µg and 20µg from standart protocol pellet => Pellet
 +
* we have 10µg and 20µg from standart protocol suspension => Super
 +
* amount of 500µl
 +
 
 +
1. Plate I(A is up)
{| border="1"
{| border="1"
-
| control, no cells || align="right" |no GOI 150µl|| align="right" |10µg 500µl
+
| 10µg dropped Super || align="right" |10µg dropped Super gently resuspending|| align="right" |10µg dropped Super gently resuspending
|-
|-
-
| control, no virus||  align="right" |no GOI 300µl||  align="right" | 10µg 750µl
+
| 10µg Super gently resuspending Super||  align="right" |20µg dropped Super gently resuspending 1:10 dilution||  align="right" | control
|-
|-
|}
|}
-
Plate II
+
2. Plate I(A is up)
{| border="1"
{| border="1"
-
| control, no cells || align="right" |no GOI 150µl|| align="right" |10µg 500µl
+
| 10µg dropped Super || align="right" |10µg dropped Super gently resuspending|| align="right" |10µg dropped Super gently resuspending
|-
|-
-
| control, no virus||  align="right" |no GOI 300µl||  align="right" | 10µg 750µl
+
| 10µg Super gently resuspending Super||  align="right" |20µg dropped Super gently resuspending 1:10 dilution||  align="right" | control
|-
|-
|}
|}
-
Plate III
+
 
 +
3. Plate I(A is up)
{| border="1"
{| border="1"
-
| control, no cells || align="right" |no GOI 150µl|| align="right" |10µg 500µl
+
| 10µg dropped Pellet || align="right" |10µg dropped Pellet gently resuspending|| align="right" |10µg dropped Pellet gently resuspending
|-
|-
-
| control, no virus||  align="right" |no virus||  align="right" | 10µg 750µl
+
| 10µg Super gently resuspending Pellet||  align="right" |20µg dropped Pellet gently resuspending 1:10 dilution||  align="right" | control
|-
|-
|}
|}
<br />
<br />
 +
 +
 +
<b>The results</b><br />
<b>The results</b><br />
 +
<gallery widths=400px heights=200px perrow=2 caption="Results of transduction with different harvested viral particles">
 +
Image:2010-7-8 plate 1 A 1.jpg|plate 1 A 1
 +
Image:2010-7-8 plate 1 A 2 solo cell.jpg|plate 1 A 2
 +
</gallery>
<br />
<br />
-
<font size="4" color="#FF0000">ADD FACS DATA</font>
+
We only took some pictures from single cells, because there was no significant difference in fluorescence between each sample.
 +
The main conclusion of this experiment is, that we have to get the flow cytometry started.
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">4.7 Transfection with different amounts of plasmids</p>===
<br />
<br />
-
The YFP expression is still quite low. This was kind of anticipated, the success in this experiment is the fact, <font size="3" color="#FF0000">that the amount of living cells is at a very high level! (~90%)</font>. <b>The conclusion</b>: Detach the cells fast! Use PBS which is not at 37°C (the PBS was 25min in the water bath), transfer the cells fast on ice after detaching!<br />  
+
<b>The motivation</b><br />
 +
We want to check if the mVenus expression and transduction efficiency can be improved with higher amounts of DNA.
 +
<br /><br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">4.7</th>
 +
<th width="100">5.7</th>
 +
<th width="100">6.7</th>
 +
<th width="100">7.7</th>
 +
<th width="100">8.7</th>
 +
<th width="100">9.7</th>
 +
<th width="100">10.7</th>
 +
<th width="100">11.7</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
The Transfection was performed with 10, 18 and 24 µg per plasmid (mVenus, pHelper and R/C).
<br />
<br />
-
<b>The next steps are</b>:
+
The virus harvest was performed according to standard protocol:
 +
* 3 Plates got transduced
 +
 
 +
1. Plate I(A is up) completely 10 µg
 +
{| border="1"
 +
| 300µl resuspended|| align="right" |300µl resuspended|| align="right" |450µl resuspended
 +
|-
 +
| 600µl resuspended||  align="right" |600µl resuspended||  align="right" | control
 +
|-
 +
|}
 +
 
 +
 
 +
2. Plate II(A is up)completely 18 µg
 +
{| border="1"
 +
| 300µl resuspended|| align="right" |300µl resuspended|| align="right" |450µl resuspended
 +
|-
 +
| 600µl resuspended||  align="right" |600µl resuspended||  align="right" | control
 +
|-
 +
|}
 +
 
 +
 
 +
3. Plate III(A is up) completely 24 µg
 +
{| border="1"
 +
| 300µl resuspended|| align="right" |300µl resuspended|| align="right" |450µl resuspended
 +
|-
 +
| 600µl resuspended||  align="right" |600µl resuspended||  align="right" | control
 +
|-
 +
|}
 +
<b>The results</b><br />
 +
FACS analysis of different treated HT1080 cells was done (18 samples)
 +
 
 +
The first percentage refers to the living and fluorescent cells and the second percentage to the total amout of living cells.
 +
 
 +
The data are listed this way:
 +
 
 +
1. Plate I(A is up)
 +
{| border="1"
 +
|A1|| align="right" |A2|| align="right" |A3
 +
|-
 +
|B1||  align="right" |B2||  align="right" |B3
 +
|-
 +
|}
 +
 
 +
1=  Plate 1 A1 : 0% YFP-positive Cells (there were only a few cells in this sample)<br>
 +
2=  Plate 1 A2 : 27,7% YFP-positve Cells  from 73,3% <br>
 +
3=  Plate 1 A3 : 17,3%      "            from 63,1% <br>
 +
4=  Plate 2 A1 : 32,9%      "            from 75,3% <br>
 +
5=  Plate 2 A2 : 27,2%      "            from 76,5% <br>
 +
6=  Plate 2 A3 : 30,7%      "            from 73,4% <br>
 +
7=  Plate 3 A1 : 26,8%      "            from 76,0% <br>
 +
8=  Plate 3 A2 : 30,5%      "            from 74,2% <br>
 +
9=  Plate 3 A3 : 30,7%      "            from 75,2% <br>
 +
10= Plate 1 B1 : 6,25%      "            from 36,1% <br>
 +
11= Plate 1 B2 : 6,42%      "            from 68,4% <br>
 +
12= Plate 1 B3 : 0,05%      "            from 89,5% <br>
 +
13= Plate 2 B1 : 20,5%      "            from 72,5% <br>
 +
14= Plate 2 B2 : 15,7%      "            from 73,6% <br>
 +
15= Plate 2 B3 : 0,02%      "            from 85,4% <br>
 +
16= Plate 3 B1 : 19,5%      "            from 73,3% <br>
 +
17= Plate 3 B2 : 20,8%      "            from 75,7% <br>
 +
18= Plate 3 B3 : 0,07%      "            from 84,8% <br>
 +
 
 +
 
 +
Conclusions
 +
* Higher amounts of Plasmids (24, 30µg) seems to have no obvious effect on YFP expression
 +
* Theres no difference in YFP expression comparing resuspended samples to not resuspended samples
 +
* The amount of dead HT cells is about 25%, it is not clear if it is either AAV induced or mechanic stress (Trypsin, washing procedure)
 +
 +
Next steps:
 +
 
 +
* does the amount of GOI (ng plasmids) has an effect on YFP expression 
 +
* compare transduced to non transduced cells (vitality), or in other words is the mechanic stress responsible for 25% dead cell ratio?
 +
* comparison of transduction efficiency of different virus stock production routines
<br />
<br />
-
<ul>
 
-
<li>Is it possible, that freeze/thaw circles reduce the transduction efficiency?</li>
 
-
<li>Why is the YFP-expression that low? (~28-30%) </li>
 
-
</ul>
 
-
===<p style="font-size:17px; background-color:#00dd77;">12.8 Virus production, seeding A431 cells </p>===
 
 +
===<p style="font-size:17px; background-color:#00dd77;">14.7 Seeding AAV293 for TKGMK constructs </p>===
<br />
<br />
<b>The motivation</b><br />
<b>The motivation</b><br />
-
In first place we want to create new stock of AAV without GOI, the next viral stock is with correct TK/GMK, the last stocks are with different YFP-amounts to check if the amount of GOI is a critical step for transduction effency (transgene expression).<br />
+
We want to create the first viral particles with TKGMK as gene of interest.
 +
<br /><br />
<b>The plan</b><br />
<b>The plan</b><br />
-
See transduction protocoll for further information, the final cantrifugation step was done with 2000 g 5 min.<br />
+
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">14.7</th>
 +
<th width="100">15.7</th>
 +
<th width="100">16.7</th>
 +
<th width="100">17.7</th>
 +
<th width="100">18.7</th>
 +
<th width="100">19.7</th>
 +
<th width="100">20.7</th>
 +
<th width="100">21.7</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
30µg Plasmid were used (pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30)<br>
 +
VIRUS no GOI :pHelper + pAAV_RC<br>
 +
VIRUS 1  :pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30 clone 1 : P54<br>
 +
VIRUS 2  :pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30 clone 2 : P55<br>
 +
VIRUS 3  :pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30 clone 3 : P56<br>
 +
<br>
 +
 
 +
<br />
<b>The results</b><br />
<b>The results</b><br />
-
Ten viral stocks with 3 ml each were prepared.
+
Unfortunately the stocks never were used (exception: see following experiment, 7. august) because later on we noticed that the TKGMK plasmids were not in line with the RFC.
 +
 
 +
 
 +
<br />
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">7.8 Seeding AAV293 for TKGMK and mVenus stocks</p>===
 +
 
 +
<b>The motivation</b>
 +
After proofing the successfull transduction of tumor cells with the reportergen mVenus the next step is to kill the cells with a prodrug approach. The prodrug of our choice is the guanosine anolog ganciclovir, once activated ganciclovir gets integrated into the growing dna chain which results in termination of dna synthesis and cell death. We transduce the tumor cell line HT1080 with viral particles packed with the thymidine kinase guanosine mono phosphate kinase fusion protein (TKGMK) as gene of interest and the incubation with ganciclovir should kill the cells.<br />
 +
<br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">7.8</th>
 +
<th width="100">8.8</th>
 +
<th width="100">9.8</th>
 +
<th width="100">10.8</th>
 +
<th width="100">11.8</th>
 +
<th width="100">12.8</th>
 +
<th width="100">13.8</th>
 +
<th width="100">14.8</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>FACS and microscopy</td>
 +
</tr>
 +
</table>
<br />
<br />
{| border="1"
{| border="1"
Line 193: Line 515:
| 2||  align="right" |6,6 ||  align="right" | 3,3||  align="right" | no GOI
| 2||  align="right" |6,6 ||  align="right" | 3,3||  align="right" | no GOI
|-
|-
-
| 3||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 TK_GMK clone1
+
| 3||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 TK_GMK clone1 (P54)
|-
|-
-
| 4||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 TK_GMK clone1
+
| 4||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 TK_GMK clone1 (P54)
|-
|-
-
| 5||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 TK_GMK clone2
+
| 5||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 TK_GMK clone2 (P55)
|-
|-
| 6||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 YFP
| 6||  align="right" |3,3 ||  align="right" | 3,3||  align="right" | 3,3 YFP
Line 210: Line 532:
|-
|-
|}
|}
-
<br />
+
<br />The transduction was performed according to standard protocol.
-
<b>The nomenclature of the plasmids is wrong, the date is 12.8. not 13.8</b>
+
Plate 1:<br />
-
===<p style="font-size:17px; background-color:#00dd77;">13.8 Seeding HT1080 for transduction at saturday, Seeding HEK293 for transfection</p>===
+
-
 
+
-
<br />
+
-
<b>The motivation</b>
+
-
 
+
-
 
+
-
<b>The plan</b><br />
+
-
 
+
-
Platte 1:<br />
+
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 244: Line 557:
</table>
</table>
<br />
<br />
-
Platte 2:<br />
+
Plate 2:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 267: Line 580:
</table>
</table>
<br />
<br />
-
Platte 3:<br />
+
Plate 3:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 290: Line 603:
</table>
</table>
<br />
<br />
-
Platte 4:<br />
+
Plate 4:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 313: Line 626:
</table>
</table>
<br />
<br />
-
Platte 5:<br />
+
Plate 5:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 336: Line 649:
</table>
</table>
<br />
<br />
-
Platte 6:<br />
+
Plate 6:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 359: Line 672:
</table>
</table>
<br />
<br />
-
Platte 7:<br />
+
Plate 7:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 382: Line 695:
</table>
</table>
<br />
<br />
-
Platte 8:<br />
+
Plate 8:<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 404: Line 717:
</tr>
</tr>
</table>
</table>
 +
<br />
<br />
-
<b>The results</b><br />
+
The test for functionality for TK GMK was done with the Prodrug Cymeven ganciclovir 500mg from Roche. The final concentration was 0,05 mM in the wells. After two days pictures were taken.
 +
 
<br />
<br />
 +
 +
<br />
<br />
-
<gallery widths=500px heights=300px perrow=2 caption="Death to HT1080">
+
<b>The results</b><br />
 +
<gallery widths=300px heights=300px perrow=2 caption="Death to HT1080">
Image:HT negativ control ganciclovir only.jpg|HT1080 with gancliclovir only
Image:HT negativ control ganciclovir only.jpg|HT1080 with gancliclovir only
Image:HT TKGMK clone 1 ohne Ganciclovir 300µl.jpg|HT1080 with TK_GMK without ganciclovir
Image:HT TKGMK clone 1 ohne Ganciclovir 300µl.jpg|HT1080 with TK_GMK without ganciclovir
Image:HT TKGMK clone 1 with ganciclovir 300µl.jpg|HT1080 with TK_GMK (300µl AAV stock) with ganciclovir  
Image:HT TKGMK clone 1 with ganciclovir 300µl.jpg|HT1080 with TK_GMK (300µl AAV stock) with ganciclovir  
Image:HT TKGMK clone 1 with ganciclovir 600µl well 2.jpg|HT1080 with TK_GMK (600µl AAV stock) with ganciclovir
Image:HT TKGMK clone 1 with ganciclovir 600µl well 2.jpg|HT1080 with TK_GMK (600µl AAV stock) with ganciclovir
 +
Image:Freiburg10 HT YFP 40µg 300µl.jpg| picture from the 40µg stock
</gallery>
</gallery>
-
<br />
 
-
<b>16.8</b>: The fluorescence was <font size="4" color="#FF0000">quite low (~ 5%)in nearly every well!</font> The 40µg YFP wells were the only exception. <br />
+
As you can see, the TKGMK cell killing mechanism works! The samples with targeted mVenus constructs couldnt be checked because the FACS machine was not working. The fluorescence was checked with microscopy, the transduction efficiency is still low.
-
<br />
+
 
-
<b>The conclusions</b><br />
+
===<p style="font-size:17px; background-color:#00dd77;"><b>14.8 Seeding different amounts of AAV293 for transfection</b></p>===
-
The incubation step of CaCl<sub>2</sub> seems to be crucial! <font size="4" color="#FF0000">The next transfection protocol is with a 30 min incubation on ice step!</font> 
+
-
<b>Seeding HEK293 for transfection at monday 16.8 </b><br />
+
-
<br />
+
<b>The motivation</b><br />
<b>The motivation</b><br />
 +
We want to know which confluence of AAV293 cells is optimal for AAV production.<br />
<br />
<br />
-
Which confluence of HEK293 cells is optimal for AAV production?<br />
+
<b>The plan</b>
-
<br />
+
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
-
<b>The plan</b><br />
+
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">14.8</th>
 +
<th width="100">15.8</th>
 +
<th width="100">16.8</th>
 +
<th width="100">17.8</th>
 +
<th width="100">18.8</th>
 +
<th width="100">19.8</th>
 +
<th width="100">20.8</th>
 +
<th width="100">21.8</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
<br />
<br />
-
We seed different amounts of cells, and check the highest titer.<br />
+
We seed different amounts of cells in 10 cm<sup>2</sup>, and check the highest titer.<br />
<br />
<br />
{| border="1"
{| border="1"
-
| Plate  || align="right"  |amount of cells
+
| Plate  || align="right"  |amount of seeded AAV-293 cells
|-
|-
| 1||  align="right" |100 000  
| 1||  align="right" |100 000  
Line 451: Line 789:
| 9||  align="right" |1 750 000
| 9||  align="right" |1 750 000
|-
|-
-
| 10|| align="right" |1 750 000 not sure
+
| 10|| align="right" |1 750 000
|-
|-
|}
|}
-
<br />
 
-
<b>The results</b>
 
-
<br />
 
-
<br />
 
-
===<p style="font-size:17px; background-color:#00dd77;">Fluorescence microscopy of transduction at 14.8 transfection of plates from 13.8</p>===
 
-
<b>Working steps</b>:
 
-
<ol>
 
-
<li>Remove the three plasmids to be co-transfected (the recombinant  pAAV expression plasmid or control plasmid, pAAV-RC, and pHelper)  from storage at –20°C.</li>
 
-
<li>Pipet <font size="4" color="#FF0000">XXX µg</font> of each of the three plasmid DNA solutions into an eppi. The standart protocol  is: 10 µg per plasmid, experiment data showed that the amounts (3,3 µg, 6,6 µg and 10 µg per plasmid) showed similar results</li>
 
-
<li>Fill up to 300 µl with sterile water. Add 300µl of 0.5 M CaCl2 and mix gently<font size="4" color="darkgreen">Incubation step 45 min on ice !!!!!!  </font></li>
 
-
<li>Pipet 600 µl ml of 2 × HBS  into a 15-ml falcon.</li>
 
-
<li>Vortex the falcon (with the 2x HBS) gently!!!! while pipetting the DNA/CaCl2 solution dropwise into the falcon (use the Pipetus).</li>
 
-
<li>Apply the DNA/CaCl<sub>2</sub>/HBS suspension to the plate of cells in a dropwise fashion<font size="4" color="#FF0000">(experimental data shows that resuspending-fashion is better for high titer)</font>, swirling gently to distribute the DNA suspension evenly in the medium.</li>
 
-
<li>Return the tissue culture plate to the 37°C room for 6 hours.</li>
 
-
<li>At the end of the incubation period, remove the medium from the plate and wash cells with warm PBS, replace it with 10 ml of fresh DMEM growth medium.<font size="4" color="#FF0000">This is a crucial step! The transfection-stress kills nearly all cells if theres no medium change</font></li>
 
-
<li>Return the plate to the 37°C incubator for an additional 72 hours.</li>
 
-
</ol>
 
-
<br />
 
-
<h3>Seeding HT1080</h3>
 
-
<b>The motivation</b>
+
The cells were transfected with 40µg standard CMV_YFP, 3,3µg Rep/Cap and 3,3µg pHelper.  
-
<br />
+
 
-
We want to check if the amount of HT cells is crucial for Transduction (The second transduction was daone with 30.000 cells, and had a high YFP expression)<br />
+
Transduction was performed according to standard protocol.
-
<br />
+
-
<b>The plan</b>
+
-
<br />
+
-
3* 6er dishes with 100.000 cells and 2* 6er dishes with 50.000 cells were seeded.
+
-
<br />
+
-
<b>The results</b><br />
+
-
<font size="4" color="#F0000">FILL IN PICTURES</font>
+
-
<br />
+
-
<h3>Seeding AAV293</h3>
+
-
<b>The motivation</b>
+
-
<br />
+
-
We want to create new viral stocks.
+
-
<br />
+
-
<b>The plan</b>
+
-
<br />
+
-
15 * 10 cm<sup>2</sup> with 2.000.000 cells on each plate were created
+
-
<br />
+
-
<h2>17.8 Transduction of plates with different amounts of cells</h2>
+
-
<b>The plan</b><br />
+
<br />
<br />
-
Platte 1 YFP: 50.000 cells per well<br />
+
Plate 1 YFP: 200.000 cells per well<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 509: Line 809:
<td>A</td>
<td>A</td>
<td>control, no cells</td>
<td>control, no cells</td>
-
<td>300µl virus </td>
+
<td>165µl virus (1) </td>
-
<td>300µl virus </td>
+
<td>165µl virus (2) </td>
</tr>
</tr>
<tr>
<tr>
<td>B</td>
<td>B</td>
<td>control, no virus</td>
<td>control, no virus</td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (1) </td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (2) </td>
</tr>
</tr>
</table>
</table>
-
Platte 2 YFP: 50.000 cells per well<br />
+
Plate 2 YFP: 200.000 cells per well<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 531: Line 831:
<td>A</td>
<td>A</td>
<td>control, no cells</td>
<td>control, no cells</td>
-
<td>300µl virus </td>
+
<td>165µl virus (3) </td>
-
<td>300µl virus </td>
+
<td>165µl virus (4) </td>
</tr>
</tr>
<tr>
<tr>
<td>B</td>
<td>B</td>
<td>control, no virus</td>
<td>control, no virus</td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (3) </td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (4) </td>
</tr>
</tr>
</table>
</table>
-
Platte 2 YFP: 50.000 cells per well<br />
+
Plate 3 YFP: 200.000 cells per well<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 553: Line 853:
<td>A</td>
<td>A</td>
<td>control, no cells</td>
<td>control, no cells</td>
-
<td>300µl virus </td>
+
<td>165µl virus (5) </td>
-
<td>300µl virus </td>
+
<td>165µl virus (6) </td>
</tr>
</tr>
<tr>
<tr>
<td>B</td>
<td>B</td>
<td>control, no virus</td>
<td>control, no virus</td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (5) </td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (6) </td>
</tr>
</tr>
</table>
</table>
-
Platte 3 YFP: 100.000 cells per well<br />
+
Plate 4 YFP: 200.000 cells per well<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 576: Line 876:
<td>A</td>
<td>A</td>
<td>control, no cells</td>
<td>control, no cells</td>
-
<td>300µl virus </td>
+
<td>165µl virus (7) </td>
-
<td>300µl virus </td>
+
<td>165µl virus (8) </td>
</tr>
</tr>
<tr>
<tr>
<td>B</td>
<td>B</td>
<td>control, no virus</td>
<td>control, no virus</td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (7) </td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (8) </td>
</tr>
</tr>
</table>
</table>
-
Platte 4 YFP: 100.000 cells per well<br />
+
Plate 5 YFP: 200.000 cells per well<br />
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 599: Line 899:
<td>A</td>
<td>A</td>
<td>control, no cells</td>
<td>control, no cells</td>
-
<td>300µl virus </td>
+
<td>165µl virus (9) </td>
-
<td>300µl virus </td>
+
<td>165µl virus (10)</td>
</tr>
</tr>
<tr>
<tr>
<td>B</td>
<td>B</td>
<td>control, no virus</td>
<td>control, no virus</td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (9) </td>
-
<td> 300µl virus </td>
+
<td> 165µl virus (10)</td>
</tr>
</tr>
</table>
</table>
 +
<b>The results</b><br />
 +
The FACS was still not available but we could easily detect a significant higher YFP expression (70-80%) at the following positions:
 +
* Plate 1: A2 and B2, A3 and B3
 +
* Plate 2: A2 and B2, A3 and B3
 +
Therefore we conclude that we have to seed between 100000 and 500000 cells for optimal virus production precedure.
-
Platte 5 TKGMK: 100.000 cells per well<br />
+
===<p style="font-size:17px; background-color:#00dd77;">17.8 transduction with viral stocks 20 µg and 40 µg GOI-plasmid</p>===
-
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
+
<b>The Motivation</b><br />
 +
We want to FACS our stocks to get valid data for further investigation of optimal virus assembly. Therefore created stocks with 20 and 40 µg CMV_mVenus.
 +
<br /><b>The Plan</b><br />
 +
<br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
-
<th width="80"> </th>
+
<th width="100">Days</th>
-
<th width="80">1</th>
+
<th width="100">17.8</th>
-
<th width="80">2</th>
+
<th width="100">18.8</th>
-
<th width="80">3</th>
+
<th width="100">19.8</th>
-
 
+
<th width="100">20.8</th>
 +
<th width="100">21.8</th>
 +
<th width="100">22.8</th>
 +
<th width="100">23.8</th>
 +
<th width="100">24.8</th>
</tr>
</tr>
<tr>
<tr>
-
<td>A</td>
+
<td>Action</td>
-
<td>control, no cells</td>
+
<td>seeding AAV293</td>
-
<td>300µl virus </td>
+
<td>-</td>
-
<td>300µl virus </td>
+
<td>Transfection</td>
-
</tr>
+
<td>-</td>
-
<tr>
+
<td>Seeding HT</td>
-
<td>B</td>
+
<td>Harvest + Transduction</td>
-
<td>control, no virus</td>
+
<td></td>
-
<td> 300µl virus </td>
+
<td>FACS</td>
-
<td> 300µl virus </td>
+
</tr>
</tr>
</table>
</table>
-
<h2>18.8 Transfection </h2>
 
-
 
-
<b>The Motivation </b><br />
 
<br />
<br />
-
Transfection with different amounts of REP/CAP and pHELPER. Additionally a
+
<li>1. plate 50.000 cells, YFP
-
<b>The plan</b><br />
+
{| align=right
-
<br />
+
|}
-
====<p style="font-size:15px; background-color:#66bbff;">'''Transfection of AAV293 cells'''</p>====
+
{| border="1"
 +
!A
 +
|control no cells
 +
|300 µl virus (40 µg YFP)
 +
|300 µl virus (20 µg YFP)
 +
|-
 +
!B
 +
|control no virus
 +
|500µl P38 (pAAV2_mVenus)
 +
|1000µl P38 (pAAV2_mVenus)
 +
|-
 +
|}
 +
<li>2. plate 50.000 cells, YFP
 +
{| align=right
 +
|}
 +
{| border="1"
 +
!A
 +
|control no cells
 +
|300 µl virus (40 µg YFP)
 +
|300 µl virus (20 µg YFP)
 +
|-
 +
!B
 +
|control no virus
 +
|500µl P38 (pAAV2_mVenus)
 +
|1000µl P38 (pAAV2_mVenus)
 +
|-
 +
|}
 +
<li>3. plate 100.000 cells, YFP 
 +
{| align=right
 +
|}
 +
{| border="1"
 +
!A
 +
|control no cells
 +
|300 µl virus (40 µg YFP)
 +
|300 µl virus (20 µg YFP)
 +
|-
 +
!B
 +
|control no virus
 +
|500µl P38 (pAAV2_mVenus)
 +
|1000µl P38 (pAAV2_mVenus)
 +
|-
 +
|}
 +
<li>4. plate 100.000 cells, YFP
 +
{| align=right
 +
|}
 +
{| border="1"
 +
!A
 +
|control no cells
 +
|300 µl virus (40 µg YFP)
 +
|300 µl virus (20 µg YFP)
 +
|-
 +
!B
 +
|control no virus
 +
|500µl P38 (pAAV2_mVenus)
 +
|1000µl P38 (pAAV2_mVenus)
 +
|-
 +
|}
 +
<b>The Results</b><br />
 +
Although we were told that the FACS would be available in time it wasn't. So the cells could unfortunately not be checked for their YFP expression =(.
-
<b> Investigator:</b> Adrian, Kerstin
+
===<p style="font-size:17px; background-color:#00dd77;">16.8 Seeding AAV293 for transfection with new R/C</p>===
-
* 2x10<sup>6</sup> cells were seeded (instead of 3x10<sup>6</sup>) --> hopefully better virus-production
+
<b>The motivation</b> <br />
 +
We want examine the functionality of different R/C constructs and the new eGFP gene of interest. This transfection was performed with new AAV-293 cells which were thawed.
 +
 
 +
 
 +
<b>The plan</b> <br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">16.8</th>
 +
<th width="100">17.8</th>
 +
<th width="100">18.8</th>
 +
<th width="100">19.8</th>
 +
<th width="100">20.8</th>
 +
<th width="100">21.8</th>
 +
<th width="100">22.8</th>
 +
<th width="100">23.8</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
* 2x10<sup>6</sup> cells were seeded
* used plasmids:  
* used plasmids:  
**P50  c= 429 ng/µl (RC)
**P50  c= 429 ng/µl (RC)
Line 652: Line 1,048:
**P158a c= 1770ng/µl (RC mutant)  
**P158a c= 1770ng/µl (RC mutant)  
 +
The transfection was performed according to standard protocol.
-
* <b> 1. plate:</b> Lipo-Transfection
+
* <b> 1. plate:</b> Lipo-Transfection => named Lipo
-
* <b> 2. plate:</b> Lipo-Transfection
+
* <b> 2. plate:</b> Lipo-Transfection => named Lipo
 +
* <b> 3. plate:</b> 3,3 µg (RC), 3,3 µg (pHelper), 3,3 µg (YFP) => was not used for transduction
 +
* <b> 4. plate:</b> 10 µg (RC), 10 µg (pHelper), 3,3 µg (YFP) => named CaCl<sub>2</sub>
 +
* <b> 5. plate:</b> 10 µg (RC mutant P158a), 10 µg (pHelper), 3,3 µg (YFP)=> CaCl<sub>2</sub> 10 µg RC mutant P158a
 +
* <b> 6. plate:</b> 10 µg (RC mutant P158b), 10 µg (pHelper), 3,3 µg (YFP)=> CaCl<sub>2</sub> 10 µg RC mutant P158b
 +
* <b> 7. plate:</b> 3,3 µg (RC mutant P158a), 3,3 µg (pHelper), 3,3 µg (YFP)=> CaCl<sub>2</sub> 3,3 µg RC mutant P158a
 +
* <b> 8. plate:</b> 3,3 µg (RC mutant P158b), 3,3 µg (pHelper), 3,3 µg (YFP)=> CaCl<sub>2</sub> 3,3 µg RC mutant P158b
 +
* <b> 9. plate:</b> 10 µg (RC), 10 µg (pHelper), 3,3 µg (eGFP)=> CaCl<sub>2</sub> eGFP 3,3 µg
 +
* <b> 10. plate:</b> 10 µg (RC), 10 µg (pHelper), 10 µg (eGFP)=> CaCl<sub>2</sub> eGFP 10 µg
 +
* <b> 11. plate:</b> 10 µg (RC), 10 µg (pHelper), 20 µg (eGFP)=> CaCl<sub>2</sub> eGFP 20 µg
 +
* <b> 12. plate:</b> 10 µg (RC), 10 µg (pHelper), 40 µg (eGFP)=> CaCl<sub>2</sub> eGFP 40 µg
 +
<b>The results</b> <br />
-
* <b> 3. plate:</b> 3,3 µg (RC), 3,3 µg (pHelper), 3,3 µg (YFP)
+
[[Image:Freiburg10 23.8.2010 FACS eGFP Lipofection 200.000.jpg|800px]]
-
* <b> 4. plate:</b> 10 µg (RC), 10 µg (pHelper), 3,3 µg (YFP)
+
-
* <b> 5. plate:</b> 10 µg (RC mutant P158a), 10 µg (pHelper), 3,3 µg (YFP)
+
-
* <b> 6. plate:</b> 10 µg (RC mutant P158b), 10 µg (pHelper), 3,3 µg (YFP)
+
-
* <b> 7. plate:</b> 3,3 µg (RC mutant P158a), 3,3 µg (pHelper), 3,3 µg (YFP)
+
-
* <b> 8. plate:</b> 3,3 µg (RC mutant P158b), 3,3 µg (pHelper), 3,3 µg (YFP)
+
-
* <b> 9. plate:</b> 10 µg (RC), 10 µg (pHelper), 3,3 µg (eGFP)
+
-
* <b> 10. plate:</b> 10 µg (RC), 10 µg (pHelper), 10 µg (eGFP)
+
-
* <b> 11. plate:</b> 10 µg (RC), 10 µg (pHelper), 20 µg (eGFP)
+
-
* <b> 12. plate:</b> 10 µg (RC), 10 µg (pHelper), 40 µg (eGFP)
+
-
===<p style="font-size:17px; background-color:#00dd77;">20.8</p>===
+
As you can see the eGFP constructs worked very well. And even the transduction efficiency of the standard R/C is ok, the conclusion is that in previous transfections the AAV293 cells were to confluent so their transfection capability. The confluence of the cells is crucial! It also seems that our used amounts of plasmids had no decisive effect on the YFP expression because of the obviously variating results. A final conclusion is still due.
-
<b>The Motivation</b><br />
+
===<p style="font-size:17px; background-color:#00dd77;">19.8 Seeding AAv293 for transfection with different HBS buffers </p>===
-
Seeding HT1080 for transfection with viral stocks from 18.8
+
-
<br />
+
-
<b>The Plan</b><br />
+
-
We harvest <b>four</b> T75 flasks and seed them into 6er dishes (200.000 cells in each well)
+
-
<br />
+
-
<b>the Results</b><br />
+
-
<br />
+
-
<br />The Facs data at 22.8
+
-
===<p style="font-size:17px; background-color:#00dd77;">21.8 Fluorescence microscopy, Transfection, AAV-Harvesting and Transduction</p>===
 
-
 
-
 
-
<h3>Transfection with different HBS-Buffers and with stratagene standard protocol</h3>
 
<b>The Motivation</b><br />
<b>The Motivation</b><br />
-
Transfection of AAV293 cells from 19.8 (ten 10cm<sup>2</sup> dishes with 2.000.000 cells each) <font size="4" color="#F0000">with original standard protocoll!!!</font> We want to try different 2xHBS Buffers (pH) and their influence on transfection efficiency!<br /><br />
+
We want to try different 2xHBS Buffers (pH) and their influence on transfection efficiency!<br /><br />
<b>The Plan</b><br />
<b>The Plan</b><br />
-
<br />
+
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
-
<b>Requiered goods</b>: 0,5 M CaCl<sub>2</sub> , 2x HBS-Buffer , autoclaved millipore water, falcons, eppis, sven's vortexer sterilized with EtOH
+
<tr>
-
<br />
+
<th width="100">Days</th>
-
<b>Working steps</b>:
+
<th width="100">19.8</th>
-
<ol>
+
<th width="100">20.8</th>
-
<li>Remove the three plasmids to be co-transfected (the recombinant  pAAV expression plasmid or control plasmid, pAAV-RC, and pHelper)  from storage at –20°C.</li>
+
<th width="100">21.8</th>
-
<li>Pipet 10 µg of each of the three plasmid DNA solutions into an eppi.</li>
+
<th width="100">22.8</th>
-
<li>Fill up to 300 µl with sterile water. Add 300µl of 0.5 M CaCl2 and mix gently</li>
+
<th width="100">23.8</th>
-
<li>Pipet 600 µl ml of 2 × HBS  into a 15-ml falcon.</li>
+
<th width="100">24.8</th>
-
<li>Vortex the falcon (with the 2x HBS) gently!!!! while pipetting the DNA/CaCl2 solution dropwise into the falcon (use the Pipetus).</li>
+
<th width="100">25.8</th>
-
<li>Apply the DNA/CaCl<sub>2</sub>/HBS suspension to the plate of cells in a dropwise fashion, swirling gently to distribute the DNA suspension evenly in the medium.</li>
+
<th width="100">26.8</th>
-
<li>Return the tissue culture plate to the 37°C room for 6 hours.</li>
+
</tr>
-
<li>At the end of the incubation period, remove the medium from the plate and wash cells with warm PBS, replace it with 10 ml of fresh DMEM growth medium.</li>
+
<tr>
-
<li>Return the plate to the 37°C incubator for an additional 72 hours.</li>
+
<td>Action</td>
-
</ol>
+
<td>seeding AAV293</td>
-
<br />
+
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td></td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
 
We try 5 different 2xHBS buffers:
We try 5 different 2xHBS buffers:
-
<font size="4" color="#FF0000"><ul>
+
<ul>
<li>pH: 7.06</li>
<li>pH: 7.06</li>
<li>pH: 7.08</li>
<li>pH: 7.08</li>
Line 711: Line 1,107:
<li>pH: 7.12</li>
<li>pH: 7.12</li>
<li>pH: 7.14</li>
<li>pH: 7.14</li>
-
</ul></font>
+
</ul>
<br />
<br />
-
<br />
+
 
-
The transfected cells were seeded at 19.8 (2.000.000 cells per 10 cm<sup>2</sup>)
+
Used Plasmids: 10µg of each plasmid
-
<br />
+
-
Used Plasmids: Standart protocol: 10µg of each plasmid
+
<ul>
<ul>
<li>GOI: mVENUS => P262, conc:1148ng/µl; used amount: 8,71µl</li>
<li>GOI: mVENUS => P262, conc:1148ng/µl; used amount: 8,71µl</li>
Line 724: Line 1,118:
</ul>
</ul>
<br />
<br />
-
<ol>
+
*Transduction of three 6-well plates:
-
<li>Remove the three plasmids to be co-transfected (the recombinant  pAAV expression plasmid or control plasmid, pAAV-RC, and pHelper)  from storage at –20°C.</li>
+
-
<li>Pipet 10 µg of each of the three plasmid DNA solutions into an eppi.</li>
+
-
<li>Add 1000µl of 0.3 M CaCl2 and mix gently</li>
+
-
<li>Pipet 1000 µl ml of 2 × HBS  into a 15-ml falcon.</li>
+
-
<li>Pipett the DNA/CaCl2 solution dropwise into the falcon (use the Pipetus).</li>
+
-
<li>Apply the DNA/CaCl<sub>2</sub>/HBS suspension to the plate of cells in a dropwise fashion, swirling gently to distribute the DNA suspension evenly in the medium.</li>
+
-
<li>Return the tissue culture plate to the 37°C room for 6 hours.</li>
+
-
<li>At the end of the incubation period, remove the medium from the plate and wash cells with warm PBS, replace it with 10 ml of fresh DMEM growth medium.</li>
+
-
<li>Return the plate to the 37°C incubator for an additional 72 hours.</li>
+
-
</ol>
+
-
<br />
+
-
Eight new viral stocks were made with pHelper:20µl and RepCap:7,41µl each:<br />
+
-
<ol>
+
-
<li>mVenus:8,71µl; pH of 2xHBS:7,06</li>
+
-
<li>mVenus:8,71µl; pH of 2xHBS:7,08 </li>
+
-
<li>mVenus:8,71µl; pH of 2xHBS:7,10 </li>
+
-
<li>mVenus:8,71µl; pH of 2xHBS:7,12 </li>
+
-
<li>mVenus:8,71µl; pH of 2xHBS:7,14 </li>
+
-
<li>TKGMK:6,67µl; pH of 2xHBS:7,08</li>
+
-
<li>TKGMK:6,67µl; pH of 2xHBS:7,10</li>
+
-
<li>TKGMK:6,67µl; pH of 2xHBS:7,12</li>
+
-
</ol>
+
-
<br />
+
-
<br />
+
-
<b>the Results</b><br />
+
-
AAV-Harvesting is at 24.8, same day Transduction and FACS will be done at 26.8
+
-
[[Image:Freiburg10 26.8.2010 FACES different 2xHBS buffers.jpg|800px]]
+
Plate 1 YFP: 150.000 cells per well<br />
 +
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="80"> </th>
 +
<th width="80">1</th>
 +
<th width="80">2</th>
 +
<th width="80">3</th>
-
<br />
+
</tr>
-
<h3>Harvesting viral stock from 18.8.2010 and following transduction</h3><br />
+
<tr>
-
<b>the motivation</b><br />
+
<td>A</td>
-
<br />
+
<td>control, no cells</td>
-
We want to check the efficiency of Lipo-transfection and standard transfection with different ratios of REPCAP/pHelper, additionally if the modified RC (p158a and p158b) is still functionally.
+
<td>500µl virus (1) </td>
-
<br /><br />
+
<td>500µl virus (2) </td>
-
<b>The plan</b><br />
+
</tr>
-
<br />
+
<tr>
-
Harvesting the cells with the Stratagene-standard protocoll.<br />
+
<td>B</td>
-
<br />
+
<td>control, no virus</td>
-
<b>The results</b><br />
+
<td>500µl virus (1) </td>
-
<br />
+
<td>500µl virus (2) </td>
-
13 virals stocks were created (in 2.000.000 cells per 10cm<sup>2</sup> dish):<br />
+
</tr>
-
<ol>
+
</table>
-
<li>Lipo-Transfection 1 (2µl pHelper + 0,8µl RC + 6,2 µl YFP)</li>
+
Plate 2 YFP: 150.000 cells per well<br />
-
<li>Lipo-Transfection 2 (2µl pHelper + 0,8µl RC + 6,2 µl YFP)</li>
+
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
-
<li>3,3 µg of RC, pHelper and mVenus</li>
+
<tr>
-
<li>10 µg RC, 10 µg pHelper, 3,3 µg GOI</li>
+
<th width="80"> </th>
-
<li>10µg RC P158a four times mutant, 10µg pHelper, 3,3 µg mVenus</li>
+
<th width="80">1</th>
-
<li>10µg RC P158b four times mutant, 10µg pHelper, 3,3 µg mVenus</li>
+
<th width="80">2</th>
-
<li>3,3µg RC P158a four times mutant, 3,3µg pHelper, 3,3 µg mVenus</li>
+
<th width="80">3</th>
-
<li>3,3µg RC P158b four times mutant, 3,3µg pHelper, 3,3 µg mVenus</li> (negative control)
+
-
<li>10µg RC, 10µg pHelper, 3,3µg GOI (broken arrow)</li>
+
-
<li>10µg RC, 10µg pHelper, 10µg GOI (broken arrow)</li>
+
-
<li>10µg RC, 10µg pHelper, 20µg GOI (broken arrow)</li>
+
-
<li>10µg RC, 10µg pHelper, 40µg GOI (broken arrow)</li>
+
-
<li>3,3 µg RC, 3,3 µg pHelper, 3,3 µg GOI </li>
+
-
<li>negative control</li>
+
-
<li>negative control</li>
+
-
</ol>
+
-
[[Image:Freiburg10 23.8.2010 FACS eGFP Lipofection 200.000.jpg|800px]]
+
 +
</tr>
 +
<tr>
 +
<td>A</td>
 +
<td>control, no cells</td>
 +
<td>500µl virus (3) </td>
 +
<td>500µl virus (4) </td>
 +
</tr>
 +
<tr>
 +
<td>B</td>
 +
<td>control, no virus</td>
 +
<td>500µl virus (3) </td>
 +
<td>500µl virus (4) </td>
 +
</tr>
 +
</table>
 +
Plate 3 YFP: 200.000 cells per well<br />
 +
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="80"> </th>
 +
<th width="80">1</th>
 +
<th width="80">2</th>
 +
<th width="80">3</th>
 +
</tr>
 +
<tr>
 +
<td>A</td>
 +
<td>control, no cells</td>
 +
<td>500µl virus (5) </td>
 +
<td>500µl virus (9) </td>
 +
</tr>
 +
<tr>
 +
<td>B</td>
 +
<td>control, no virus</td>
 +
<td> 500µl virus (9) </td>
 +
<td> 500µl virus (5) </td>
 +
</tr>
 +
</table>
 +
*(1)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,06
 +
*(2)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,08
 +
*(3)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,112
 +
*(4)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,12
 +
*(5)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,14
 +
<br />
 +
<b>the Results</b><br />
 +
AAV-Harvesting is at 24.8, same day Transduction and FACS will be done at 26.8
 +
[[Image:Freiburg10 CC 26.8 different HBS.jpg|800px]]
-
 
+
As you can see the 2xHBS with pH 7.112 performed best, in future experiments this buffer will be used.
-
 
+
-
<h3>Checking transduction efficiency via fluorescence microscopy</h3>
+
-
<b>the motivation</b><br />
+
<br />
<br />
-
The transduction efficiency from the viral stocks which were created with different amounts of AAV293 was checked.<br />
 
-
<b>The plan</b><br />
+
===<p style="font-size:17px; background-color:#00dd77;">22.8: Transfection of AAV293 with different amounts of cells, and two plasmid concentrations</p>===
-
<br />
+
-
<ol>
+
-
<li>plate 1:</li>
+
-
<ul><li>stock 1 (with 100.000 cells) </li>
+
-
<li>stock 2 (with 200.000 cells) </li>
+
-
</ul>
+
-
<li>plate 2:</li>
+
-
<ul><li>stock 3 (with 400.000 cells) </li>
+
-
<li>stock 4 (with 500.000 cells) </li>
+
-
</ul>
+
-
<li>plate 3:</li>
+
-
<ul><li>stock 5 (with 800.000 cells) </li>
+
-
<li>stock 6 (with 1.000.000 cells) </li>
+
-
</ul>
+
-
<li>plate 4:</li>
+
-
<ul><li>stock 7 (with 1.200.000 cells)  </li>
+
-
<li>stock 8 (with 1.500.000 cells)  </li>
+
-
</ul>
+
-
<li>plate 5:</li>
+
-
<ul><li>stock 9 (with 1.750.000 cells)  </li>
+
-
<li>stock 10 (with 1.750.000 cells)  </li>
+
-
</ul>
+
-
</ol>
+
-
<b>The results</b><br />
+
-
<br />
+
-
the optimal confluence of AAv293 cells is between 100 000 and 800 000 cells. This will be the field of investigation in the next experiments
+
-
 
+
-
<h2>25.8: Transfection of AAV293 with different amounts of cells, and two plasmid concentrations</h2>
+
<b>The motivation</b><br />
<b>The motivation</b><br />
<br />
<br />
-
We want to define the final AAV293-concentration for optimal AAV-Production
+
We want to define the final amount of AAV293 per 10 cm<sup>2</sup> for optimal AAV-Production<br />
<br />
<br />
<b>The plan</b><br />
<b>The plan</b><br />
-
<br />
 
-
<ol>
 
-
<li>100.000</li>
 
-
<li>100.000</li>
 
-
<li>200.000</li>
 
-
<li>200.000</li>
 
-
<li>300.000</li>
 
-
<li>300.000</li>
 
-
<li>400.000</li>
 
-
<li>400.000</li>
 
-
<li>500.000</li>
 
-
<li>500.000</li>
 
-
<li>600.000</li>
 
-
<li>600.000</li>
 
-
<li>700.000</li>
 
-
<li>700.000</li>
 
-
</ol>
 
-
<br />
 
-
10µg RC P158a four times mutant, 10µg pHelper, 3,3 µg mVenus P162  were pipetted on plates: 2, 4, 6, 8, 10 , 12, 14
 
-
<br />
 
-
3,3µg RC P158a four times mutant, 3,3µg pHelper, 3,3 µg mVenus P262 were pipetted on plates: 1, 3, 5, 7, 9, 11, 13
 
-
<br />
 
-
<br />
 
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 882: Line 1,235:
</tr>
</tr>
</table>
</table>
 +
The following amount of cells were seeded in 10 cm<sup>2</sup>:
 +
<ol>
 +
<li>100.000</li>
 +
<li>100.000</li>
 +
<li>200.000</li>
 +
<li>200.000</li>
 +
<li>300.000</li>
 +
<li>300.000</li>
 +
<li>400.000</li>
 +
<li>400.000</li>
 +
<li>500.000</li>
 +
<li>500.000</li>
 +
<li>600.000</li>
 +
<li>600.000</li>
 +
<li>700.000</li>
 +
<li>700.000</li>
 +
</ol>
 +
<br />
 +
10µg RC P158a four times mutant, 10µg pHelper, 3,3 µg mVenus P162  were pipetted on plates: 2, 4, 6, 8, 10 , 12, 14
 +
<br />
 +
3,3µg RC P158a four times mutant, 3,3µg pHelper, 3,3 µg mVenus P262 were pipetted on plates: 1, 3, 5, 7, 9, 11, 13
 +
<br />
 +
 +
<b>The results</b><br />
<b>The results</b><br />
Line 887: Line 1,264:
[[Image:Freiburg10 30.2010 FACS number of Cells and Beas construct.jpg|800px]]
[[Image:Freiburg10 30.2010 FACS number of Cells and Beas construct.jpg|800px]]
<br />
<br />
-
 
+
<br />
-
Data were not reliable (The amount of Goi (3,3 µg instead of 10µg) was not sufficient enough)so the average YFP expression is quite low, but the remarkable note is: Beas construct (<font size="4" color="#FF0000">pSB1C3_leftITR_CMV_betaglobin_mVenus_hGH_rightITR</font>) fusioned from the created Biobricks still works!
+
There is only one value for each approach but nevertheless the average YFP expression should be higher.
 +
We really dont know the reason for the quite low YFP expression. There are also very good news: the reassembled construct (pSB1C3_leftITR_CMV_betaglobin_mVenus_hGH_rightITR) created from the single Biobricks works as "well" as the AAV2 with CMV_mVenus!
<br/>
<br/>
<br />
<br />
<br />
<br />
-
<h2>Seeding AAV293 for 10xTransfection</h2>
+
 
 +
===<p style="font-size:17px; background-color:#00dd77;">30.8 Seeding AAV293 for Transfection of 10 cm<sup>2</sup> plates</p>===
<br />
<br />
<b>The motivation</b><br />
<b>The motivation</b><br />
We want to create ten hypothetical identical viral stocks to estimate the standard deviation.  
We want to create ten hypothetical identical viral stocks to estimate the standard deviation.  
-
<br />
+
<br /><br />
-
<b>The plan</b><br />
+
<b>The plan</b>
-
<br />
+
-
 
+
<br />
<br />
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
Line 935: Line 1,312:
</ul>
</ul>
<br />
<br />
-
0,5 ml of each stock become deepfreeze in.<br />
+
0,5 ml of each stock be stored at -80°C.<br />
<br />
<br />
-
One stock will be completely used for Transduction 9,5 ml (rest of the stock) * 0,5 ml (amount per transduction) => 19 values for estimating standard derivation.
+
9,5 ml of each stock will be used for Transduction. <br>
 +
<br>
 +
Result:
 +
<br>
 +
[[Image:Freiburg10_Unbenannt.jpg]]
 +
<br>
 +
Standard deviation: about +/- 4,98% YFP expression. All future AAV2 stocks will be pooled if produced with this same plasmids and amounts of plasmids. Unfortunately the YFP expression is still located at around 50%. We would like to have a YFP expression of at least 70% because as soon as we start to test our not yet ready modified AAV2 we suggest the YFP expression will obviously decrease.
-
<h2>getting valide data of 10µg samples</h2>
 
-
<br />
 
-
<b>The motivation</b><br />
 
-
we want to check the YFP expression
 
-
<br />
 
-
<b>The plan</b><br />
 
-
<br />
 
-
<br />
 
-
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 
-
<tr>
 
-
<th width="100">Days</th>
 
-
<th width="100">30.8</th>
 
-
<th width="100">31.8</th>
 
-
<th width="100">1.9</th>
 
-
<th width="100">2.9</th>
 
-
</tr>
 
-
<tr>
 
-
<td>Action</td>
 
-
<td>seeding HT</td>
 
-
<td>Transduction</td>
 
-
<td>-</td>
 
-
<td>FACS</td>
 
-
</tr>
 
-
</table>
 
-
<br />
 
-
One stock will be completely used for Transduction 9,5 ml (rest of the stock) * 0,5 ml (amount per transduction) => 19 values for estimating standard derivation.<br />
 
-
<br />
 
-
<b>the results</b>
 
 +
===<p style="font-size:17px; background-color:#00dd77;">4.9 Seeding cells for checking constructs (GOIs) with/without HGH and beta globin and reassembled as control </p>===
-
<h2>28.8 Checking functionality of RC vectors </h2>
 
-
<br />
 
-
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 
-
<tr>
 
-
<th width="100">Days</th>
 
-
<th width="100">28.8</th>
 
-
<th width="100">29.8</th>
 
-
<th width="100">30.8</th>
 
-
<th width="100">31.9</th>
 
-
<th width="100">1.9</th>
 
-
<th width="100">2.9</th>
 
-
<th width="100">3.9</th>
 
-
<th width="100">4.9</th>
 
-
<th width="100">5.9</th>
 
-
<th width="100">6.9</th>
 
-
</tr>
 
-
<tr>
 
-
<td>Action</td>
 
-
<td>seeding AAV293</td>
 
-
<td>-</td>
 
-
<td>-</td>
 
-
<td>Transfection</td>
 
-
<td>-</td>
 
-
<td>-</td>
 
-
<td>Harvest+Seeding HT</td>
 
-
<td>Transduction</td>
 
-
<td>-</td>
 
-
<td>FACS</td>
 
-
</tr>
 
-
</table>
 
-
<b></b>
 
-
<br />
 
-
Transfection was done with:
 
-
<ul>
 
-
<li>RepCap:P326 => 2481 ng/µl used amount: 4µl => 10µg</li>
 
-
<li>RepCap:P325 => 2051 ng/µl used amount: 4,87µl => 10µg</li>
 
-
<li>pHelper:P356 => 684 ng/µl used amount: 414,62µl => 10µg </li>
 
-
<li>mVenus:P262 => 1148 ng/µl used amount: 8,7µl => 10µg </li>
 
-
</ul>
 
-
 
-
 
-
<br />
 
-
<b>The results</b><br />
 
-
<br />
 
-
 
-
 
-
 
-
 
-
Transfection will be done with:
 
-
<ul>
 
-
<li>RepCap:P357 10µg =>conc.:1274,8ng/µl used amount: 7,84µl </li>
 
-
<li>pHelper:P356 10µg =>conc.:1068ng/µl used amount: 9,36µl </li>
 
-
<li>mVenus:P261 => excel sheet P263: 10µg =>conc.:979ng/µl used amount: 10,21 µl</li>
 
-
</ul>
 
<br />
<br />
 +
<b>The motivation</b><br />
 +
We want to check the functionality of these genes of interest
-
 
-
 
-
<h2>4.9 checking constructs (GOIs) with/without HGH and beta globin and reassembled as control</h2>
 
-
 
-
<b></b>
 
-
<br />
 
-
<b>The motivation</b><br />
 
-
We want to check if these reassmbled constructs (GOIs) still work!
 
-
<ul>
 
-
<li>P269 lITR_CMV_beta-globin_mVenus_HGH_rITR = 325 ng/µl => 9,66 µl </li>
 
-
<li>P270 lITR_CMV_beta-globin_mVenus_HGH_rITR = 561 ng/µl => 7,26 µl</li>
 
-
<li>P377 lITR_CMV_mVenus_HGH_rITR = 325,04 ng/µl => 30,76 µl  </li>
 
-
<li>P378 lITR_CMV_beta-globin_mVenus_rITR = 561 ng/µl => 17,8µl  </li>
 
-
</ul>
 
-
All constructs are completed with p50 R/C =>> 26,45 µl and pHELPER 14,61µl
 
-
<br />
 
<b>The plan</b><br />
<b>The plan</b><br />
-
<br />
 
-
<br />
 
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 1,071: Line 1,357:
</tr>
</tr>
</table>
</table>
-
<b></b>
+
<ul>
 +
<li>P269 pSB1C3_lITR_CMV_beta-globin_mVenus_HGH_rITR = 325 ng/µl => 9,66 µl </li>
 +
<li>P270 pSB1C3_lITR_CMV_beta-globin_mVenus_HGH_rITR = 561 ng/µl => 7,26 µl</li>
 +
<li>P377 pSB1C3_lITR_CMV_mVenus_HGH_rITR = 325,04 ng/µl => 30,76 µl  </li>
 +
<li>P378 pSB1C3_lITR_CMV_beta-globin_mVenus_rITR = 561 ng/µl => 17,8µl  </li>
 +
</ul>
 +
Additionally P50: pAAV_RC R/C (26,45 µl) and pHELPER (14,61µl) pipetted to each approach. <br />
<br />
<br />
-
<h2>6.9 checking five ganciclovir concentrations for two day incubation approach optimal medication</h2>
+
<br />
 +
<b>The results</b><br />
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">6.9 checking five ganciclovir concentrations for two day incubation approach optimal medication</p>===
 +
 
<br />
<br />
<b>The motivation</b><br />
<b>The motivation</b><br />
-
we want to check the optimal ganciclovir concentration, we use the TK/GMK Stocks (10 µg from each plasmid) from 24.8 with Buffer pH 7,10 and the pH12 stock.
+
We want to check the optimal ganciclovir concentration, we use the TK/GMK Stocks (10 µg from each plasmid) from 24.8 with Buffer pH 7,10 and the pH12 stock.
<br />
<br />
-
<b>The plan</b><br />
 
-
<br />
 
-
 
<br />
<br />
 +
<b>The plan</b><br />
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
Line 1,110: Line 1,404:
<br />
<br />
<b>the results</b>
<b>the results</b>
 +
<br />
<br />
<br />
[[Image:Freiburg10 CC 6.9 Checking Ganciclovir concentrations-CHART.jpg|800px]]
[[Image:Freiburg10 CC 6.9 Checking Ganciclovir concentrations-CHART.jpg|800px]]
<br />
<br />
-
<h2>22.9 Transfection with Volkers R/C constructs</h2>
 
<br />
<br />
-
<b>The motivation</b>
+
<br />
-
We want to check if these R/C still work! <br />
+
As expected the highest concentration of ganciclovir worked the best but it is remarkable that there is no significant difference between the first three ganciclovir amounts. The most remarkable note is, that in future experiments the incubation time has to be extended to 3 or 4 days.
-
<br /><b>The plan</b><br />
+
 
-
<br /><table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
+
===<p style="font-size:17px; background-color:#00dd77;">15.9 Seeding AAV293 for testing our Affibody and other VP-mVenus constructs</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
The pCerulean_VP1up_mVenus_Vp2/3 Construct will be tested in three different compositions.<br />
 +
<br />
 +
<b>The plan</b><br />
 +
We want to test these constructs:
 +
<ul>
 +
<li>pCerulean_VP1up_NLS_Affibody_VP2/3</li>
 +
<li>pCerulean_VP1up_His_VP2/3</li>
 +
<li>pCerulean_VP1up_mVenus_Vp2/3</li>
 +
</ul>
 +
The His-tag is for purify our constructs and in this case we want to test, if the particles are still infectious. Construct with the affibody will be tested for functionality and even for their better affinity to our EGFR overexpressing cell line A431.
 +
 
 +
<br />
 +
<b>The results</b><br />
 +
Interpretation and discussion of our results.
 +
<br />
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">19.9 Seeding AAV293 for checking two different Rep/Cap Constructs</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
During the project 22 silent nucleotide exchange mutations were introduced into the capsid coding construct to make it compatible with the RFC standards and to have single cutting restriction enzymes flanking the 453 and the 587 loop sequence. Two point mutations had to be dismissed, because either a first test transduction showed that the construct was not working anymore or the insertion of the synthesized gene posed serious problems, because the restriction enzyme did not work.
 +
<br />
 +
<b>The plan</b><br />
 +
Transfection and transduction was performed according to standard protocol.
 +
 
 +
<br />
 +
<b>The results</b><br />
 +
[[Image:Freiburg10 CC 19.9 FACS Checking functionality of REP CAP.jpg|800px]]
 +
<br /><br />
 +
Finally, we have a construct that is shown to produce infectious particles comparable to the current AAV systems and carries 20 point mutations. Now we can announce that the Adeno-associated Virus is compatible to the RFC standard and the idea to replace the loop sequences via ViralBricks works!
 +
<br />
 +
 
 +
 
 +
 
 +
 
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">22.9 Seeding AAV293 for transfection with different mVenus constructs for checking specific promoter activity</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
We want to check if the CMV and pTERT promoters work equaly in the AAV293, A431 and HT1080 cells. So we transfect them via standard transfection CaCl<sub>2</sub>. It is obvious that the individual cell lines are not equaliy competent to transfection (the AAV293 are optimised for transfection). It seems that this promoter is not that active in AAV293 cells.
 +
<br />
 +
<b>The plan</b><br />
 +
We transfected the three cell lines A431, AAV293 and HT1080 with following three constructs:
 +
<ul>
 +
<li>CMV_mVenus</li>
 +
<li>CMV_eGFP</li>
 +
<li>pTERT_mVenus</li>
 +
</ul>
 +
<br />
 +
Remember, that mVenus and eGFP have the exact same excitation wavelenght. We took the pictures with the same parameters, but saved the data in the wrong formate (.tif instead of .zvi), <b>so we werent able to change the YFP expression from green to yellow</b>.
 +
 
 +
<br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
<th width="100">Days</th>
<th width="100">Days</th>
-
<th width="100">20.9</th>
 
-
<th width="100">21.9</th>
 
<th width="100">22.9</th>
<th width="100">22.9</th>
<th width="100">23.9</th>
<th width="100">23.9</th>
-
<th width="100">24.9</th>
+
<th width="100">24.10</th>
-
<th width="100">25.9</th>
+
<th width="100">25.10</th>
-
<th width="100">26.9</th>
+
<th width="100">26.10</th>
-
<th width="100">27.9</th>
+
-
<th width="100">28.9</th>
+
</tr>
</tr>
<tr>
<tr>
<td>Action</td>
<td>Action</td>
-
<td>seeding AAV293: 4*6wells</td>
+
<td>seeding AAV293</td>
-
<td>-</td>
+
-
<td>Transfection: 4 constructs</td>
+
<td>-</td>
<td>-</td>
-
<td>-</td>
+
<td>Transfection</td>
-
<td>Seeding HT</td>
+
<td>fluorescence microscopy</td>
-
<td>Harvest + Transduction</td>
+
<td>fluorescence microscopy</td>
-
<td>-</td>
+
-
<td>FACS</td>
+
</tr>
</tr>
-
</table><br />
+
</table>
-
<b>The results</b>
+
<br />
-
<font size="4" color="red">on the 23.9 it was shure that something went wrong with the nomenclature, so this approach is definitely not working => threwn away!</font>
+
<gallery widths=300px heights=300px perrow=2 caption="Transfection of different cell types with different promoter_reportergenes">
 +
Image:Freiburg10 CC AAV293 16h eGFP STANDARD from Sven.jpg|AAV293 CMV_eGFP 16h post transfection
 +
Image:Freiburg10 CC AAV293 16h mVENUS reassembled1.jpg|AAV293 CMV_mVenus 16h post transfection
 +
Image:Freiburg10 CC AAV293 16h pTERT mVenus1.jpg|AAV293 pTERT_mVenus 16h post transfection
 +
Image:Freiburg10 A293 48h pTERT construct1 low light.jpg|AAV293 CMV_eGFP 48h post transfection
 +
Image:Freiburg10 48h HT1080 reassembled construct1.jpg|HT1080 CMV_mVenus 48h post transfection
 +
Image:Freiburg10_48h_A431_reassembled_construct1.jpg|A431 CMV_mVenus 48h post transfection
 +
</gallery>
 +
<br />
 +
<b>The results</b><br />
 +
As excepted, the expression of the CMV_mVenus and CMV_eGFP was very high even at 16h post transfection. The pTERT_mVenus construct worked aswell, but significantly weaker!
 +
Problematic is the fact, that there was no expression in HT1080 and A431 detectable. Due the fact that these cell lines are not optimized for CaCl<sub>2</sub> transfection. We can't evaluate if the bad transfection efficiency or the low promoter activity of pTERT are responsible for the results.
 +
<br />
-
<br /><h2>22.9 Testing of Hannas 6 VP-constructs with different compositions (10%, 25%, 50% and 75% fractions) with a VP2-knockout construct</h2>
+
===<p style="font-size:17px; background-color:#00dd77;">22.9 Testing of Hannas 6 VP-constructs with different compositions (10%, 25%, 50% and 75% fractions) with a VP2-knockout construct</p>===
<br />
<br />
<b>The motivation</b>
<b>The motivation</b>
-
<br /> Test the 18 constructs for functionality on A431 and HT1080 cells.<br />
+
<br /> Test the following 18 constructs for functionality on A431 and HT1080 cells. Each of these constructs getting transfected in different compositions 25%, 50%, 75% and 90% with VP2_knockout 75%. In this way we are able to create viral particles with this ratios of VP proteins. We hope that the created particles are still infectious.<br />
 +
<ul>
 +
<li>pCerulean_CFP_MiddleLinker_VP2/3insCap P528</li>
 +
<li>pCerulean_Zegfr:1907_ShortlLinker_VP2/3insCap P527</li>
 +
<li>pCerulean_6xHis_Middlelinker_VP2/3insCap P534</li>
 +
<li>pCerulean_Zegfr:1907_Middlelinker_VP2/3insCap P535</li>
 +
<li>pCerulean_Zegfr:1907_SEG_VP2/3_Capins 10:90 P502</li>
 +
<li>pCerulean_Zegfr:1907_LongLinker_VP2/3_CapIns P503</li>
 +
</ul>
 +
<br />
<b>The plan</b><br />
<b>The plan</b><br />
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
Line 1,183: Line 1,544:
<br> [[Image:Freiburg 10 FACS Linker Libary.jpg|800px]]
<br> [[Image:Freiburg 10 FACS Linker Libary.jpg|800px]]
<br />
<br />
-
<h2>22.9 Testing pTERT_mVENUS in R/C P326 and P431</h2>
+
Obviously the constructs still work!
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">22.9 Seeding cells for testing pTERT_mVenus in R/C P326 and P431 </p>===
<br />
<br />
-
<b>The motivation</b>
+
<b>The motivation</b><br />
-
We want to check if the pTERT-promoter is realiable for tumor specific gene expression. <br /><br />
+
We want to check if the pTERT-promoter is realiable for tumor specific gene expression, we use two different kinds of R/C. <br /><br />
<b>The plan</b><br />
<b>The plan</b><br />
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
Line 1,222: Line 1,585:
</tr>
</tr>
</table>
</table>
 +
<br />
 +
<b>The results</b>
<br />
<br />
 +
===<p style="font-size:17px; background-color:#00dd77;">29.9 Checking location of VP proteins via fluorescence microscopy and checking fractions of centrifugation steps via fluorescence spectrometer</p>===
<br />
<br />
-
<b>The results</b>
+
<b>The motivation</b>: We want to figure out if it is possible to purify our viral stocks via centrifugation with 10.000 g and/or 20.000 g. In theory/ according to the literature the viral particles should be in the cells and attached to the HSPGs at the cellular surfaces.
<br />
<br />
 +
<b>The plan</b>: Two different viral stocks were prepared:
 +
<br /><br />
 +
Stock 1 with VP2-mVenus-fusion-Capsid loaded with TKGMK (4 wells from a 6 well plate)<br />
 +
<ul>
 +
<li>R/C 1: 50% pCerulean_VP1up_NLS_mVenus_Vp2/3 P501</li>
 +
<li>R/C 2: 50% Rep/Cap2: P449 pAAV_RC_4fachmut_VP1-ko:</li>
 +
<li>GOI: TKGMK: P82.b</li>
 +
<li>pHelper</li>
 +
</ul>
 +
<br />
 +
Stock 2 "standard" virus (4 wells from a 6 well plate)<br />
 +
<ul>
 +
<li>R/C 1 P486</li>
 +
<li>GOI: TKGMK: P82.b</li>
 +
<li>pHelper</li>
 +
</ul>
 +
These two stocks got harvested according to standard protocol (scratching cells, transfer them in to 15 ml falcons, resuling 12ml solution total). After centrifugation (10 min 200g), the supernatant got transferred into two new 15 ml falcons and the pellets were resuspended with 10 ml DMEM Medium. The Stocks got freezed thawed two times so finally there were:
 +
<ol>
 +
<li>DMEM as negative control</li>
 +
<li>resuspended Pellet with mVenus-fusioned viral capsids</li>
 +
<li>resuspended Pellet with "standard virus"</li>
 +
<li>supernatant with mVenus-fusioned viral capsids</li>
 +
<li>supernatant with "standard virus"</li>
 +
</ol>
 +
<br />
 +
The fluorescence of each stock was measured via spectrometer. After that, stocks 2 and 4 were centrifugated 10min with 10.000 g followed by an other fluorescence measuring. Finally the stocks got spin down with 20.000 g for 10 min
 +
<br />
 +
<b>The results</b>:
 +
<br />
 +
<gallery widths=300px heights=300px perrow=2 caption="Transfection with VP-mVenus-fusion constructs">
 +
Image:Freiburg10 VP mVenus fusion localisation 1.10 Close Picture2.jpg|Picture two days post transfection.
 +
</gallery>
-
<h2>28.9 Testing Loop Insertions</h2>
 
<br />
<br />
-
<b>The motivation</b>
+
[[Image: Freiburg10 mVenus VP fusion fluorescence centrifugation experiment graph.jpg|thumb|center|800px]]
 +
<br />
 +
[[Image:Freiburg10 mVenus VP fusion fluorescence centrifugation experiment 526nm.jpg|thumb|center|800px]]
 +
<br /><b>The conclusions</b>:
 +
The highest amount of fluorescence was measured in the supernatant, the individual centrifugation steps had <b>no decrease in fluorescence</b> as consequence!
-
<b>The plan</b>
+
<br />
 +
Keep in mind, without further investigation it is not valid to say that we can purify our stocks via 10-20.000 g centrifugation steps, because we dont know if the viral capsids are still intact! The FACS analysis are not sufficient enough to make a decision, because our last samples had YFP as GOI (=> so efficient cell sorting was not possible). We need to do qPCRs to make a valid evidence.
 +
<br />
 +
<br />
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">30.9 Production of new Standard mVenus Vector</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
The AAV2 with 4 point mutations, inserted rep and cap and remutated KpnI restriction has to be checked for its functionality in order to compare it with the wild type AAV2. Hopefully there will be no significant difference.<br />
 +
<b>The plan</b><br />
 +
After the "delay" 200.000 A431 and HT1080 cells were seeded and transduced on the following day with 0,5 ml of this AAV2 mutant.
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
<tr>
<tr>
<th width="100">Days</th>
<th width="100">Days</th>
-
<th width="100">28.9</th>
 
-
<th width="100">29.9</th>
 
<th width="100">30.9</th>
<th width="100">30.9</th>
<th width="100">1.10</th>
<th width="100">1.10</th>
Line 1,246: Line 1,655:
<th width="100">5.10</th>
<th width="100">5.10</th>
<th width="100">6.10</th>
<th width="100">6.10</th>
 +
<th width="100">7.10</th>
 +
<th width="100">8.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest</td>
 +
<td>delayed because of cell death</td>
 +
<td>delayed because of cell death</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<b>The results</b><br />
 +
The stocks were harvested successfully
 +
<br />
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">30.9 Seeding AAV293 for production of standard TKGMK vector  </p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
We want to create a big amount of viral particles with TKGMK as gene of interest for using it as an standard vector for the MTT-assay.
 +
<br />
 +
<b>The plan</b><br />
 +
 +
 +
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">30.9</th>
 +
<th width="100">1.10</th>
 +
<th width="100">2.10</th>
 +
<th width="100">3.10</th>
 +
<th width="100">4.10</th>
 +
<th width="100">5.10</th>
 +
<th width="100">6.10</th>
 +
<th width="100">7.10</th>
 +
<th width="100">8.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest</td>
 +
<td>delayed because of cell death</td>
 +
<td>delayed because of cell death</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<b>The results</b><br />
 +
The viral stocks were harvested efficiently and are ready to use.
 +
<br />
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">30.9 Seeding AAV293 for production of vectors with mVenus missing beta globin</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
Beta globin is said to improve (stratagene) the expression so we expect a worse mVenus (reportergene) expression compared to the standard AAVs. Therefore the seeded A431 and HT1080 cells were transduced with a AAV2 mutant missing beta-globin.
 +
<br />
 +
<b>The plan</b><br />
 +
Ater the "delay" 200.000 HT1080 and A431 cells were seeded and transduced with 0,5 ml AAV2 mutant on the following day.
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">30.9</th>
 +
<th width="100">1.10</th>
 +
<th width="100">2.10</th>
 +
<th width="100">3.10</th>
 +
<th width="100">4.10</th>
 +
<th width="100">5.10</th>
 +
<th width="100">6.10</th>
 +
<th width="100">7.10</th>
 +
<th width="100">8.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest</td>
 +
<td>delayed because of cell death</td>
 +
<td>delayed because of cell death</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<b>The results</b><br />
 +
Interpretation and discussion of our results.
 +
<br />
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">30.9 Seeding AAV293 for production of vectors with mVenus missing HGH</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
HGH is responsible for the mRNA polyadenylation of the virus so we expect expect a worse mVenus (reportergene) expression compared to the standard AAVs. Therefore the seeded A431 and HT1080 cells were transduced with a AAV2 mutant missing HGH.
 +
<br />
 +
<b>The plan</b><br />
 +
After the "delay" 200.000 A431 and HT1080 cells were seeded and transduced on the following day with 0,5 ml AAV2 mutant missing HGH.
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">30.9</th>
 +
<th width="100">1.10</th>
 +
<th width="100">2.10</th>
 +
<th width="100">3.10</th>
 +
<th width="100">4.10</th>
 +
<th width="100">5.10</th>
 +
<th width="100">6.10</th>
 +
<th width="100">7.10</th>
 +
<th width="100">8.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest</td>
 +
<td>delayed because of cell death</td>
 +
<td>delayed because of cell death</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<b>The results</b><br />
 +
Interpretation and discussion of our results.
 +
<br />
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">30.9 Seeding AAV293 for testing RC with HSPG knockout for functionality</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
The primary AAV2 receptor (the HSPG receptor) was knocked out so we expect a worse tranduction rate (about 0,3 to 0,4 of the standard transduction rate, assuming that there are HSPGs on the HT1080 and A431 cell surface). The worse the better.
 +
<br />
 +
<b>The plan</b><br />
 +
After the "delay" 200.000 A431 and HT1080 cells were seeded and transduced on the following day with 0,5 ml AAV2 mutant with a HSPG-receptor knockout.
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">30.9</th>
 +
<th width="100">1.10</th>
 +
<th width="100">2.10</th>
 +
<th width="100">3.10</th>
 +
<th width="100">4.10</th>
 +
<th width="100">5.10</th>
 +
<th width="100">6.10</th>
 +
<th width="100">7.10</th>
 +
<th width="100">8.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest</td>
 +
<td>delayed because of cell death</td>
 +
<td>delayed because of cell death</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<b>The results</b><br />
 +
[[Image:Freiburg10 HT1080 missing HSPG binding motif.png|thumb|center|800px]]
 +
[[Image:Freiburg10 A431 missing HSPG binding motif.png|thumb|center|800px]]
 +
<br />
 +
There is a significant difference in transduction efficiency. The actual reduction is even higher than expected, according to literature it should be around 60%, we reached 80%. We measured via qPCR the amount of viral particles for each stock, and they are nearly the same the HSPG Knockout has 2*10<sup>7</sup>particles per ml , the stock with HSPG-binding motif has 4.5*10<sup>6</sup> particles per ml.
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">30.9 Seeding AAV293 for testing RC WITHOUT HSPG knockout for functionality</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
The produced vector has the intact HSPG-binding motif, so we can compare it with the vector produced in: "Seeding AAV293 for testing RC with HSPG knockout for functionality"
 +
<br />
 +
<b>The plan</b><br />
 +
Transfection and transduction were performed according to standard protocol.
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">30.9</th>
 +
<th width="100">1.10</th>
 +
<th width="100">2.10</th>
 +
<th width="100">3.10</th>
 +
<th width="100">4.10</th>
 +
<th width="100">5.10</th>
 +
<th width="100">6.10</th>
 +
<th width="100">7.10</th>
 +
<th width="100">8.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest</td>
 +
<td>delayed because of cell death</td>
 +
<td>delayed because of cell death</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<b>The results</b><br />
 +
See 30.9 Seeding AAV293 for testing RC with HSPG knockout for functionality
 +
<br />
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">12.10 Seeding AAV293 cells for transfection with VP-BAP</p>===
 +
<br />
 +
<b>The motivation</b>
 +
<br />
 +
We want to create a viral stock for purification and biotinylation, the ratio of the Rep/Cap plasmids is 1:1.<br />
 +
<b>The plan</b><br />
 +
Transfection was performed according to standard protocol:
 +
<ul>
 +
<li>Gene of interest: mVenus</li>
 +
<li>R/C: pSB1C3-001_pCMV_[AAV]VP123_587_BAP in cotransfection with pSB1C3_001_RC_IRCK_P5tataless clone 1</li>
 +
</ul>
 +
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">12.10</th>
 +
<th width="100">13.10</th>
 +
<th width="100">14.10</th>
 +
<th width="100">15.10</th>
 +
<th width="100">16.10</th>
 +
<th width="100">17.10</th>
 +
<th width="100">18.10</th>
 +
<th width="100">19.10</th>
 +
<th width="100">20.10</th>
</tr>
</tr>
<tr>
<tr>
Line 1,262: Line 1,910:
<b>The results</b>
<b>The results</b>
-
<h2>Experiments</h2>
+
===<p style="font-size:17px; background-color:#00dd77;">12.10 Seeding AAV293 cells for transfection with mVenus as gene of interest and pCerulean_VP1up_NLS_mVenus_VP2/3_HSPG-KO</p>===
-
<br /><br />
+
<br />
<b>The motivation</b>
<b>The motivation</b>
 +
<br />
 +
We want to create a viral stock for purification and biotinylation, the ratio of the Rep/Cap plasmids is 1:1.<br />
 +
<b>The plan</b><br />
 +
Transfection was performed according to standard protocol:
 +
<ul>
 +
<li>Gene of interest: mVenus</li>
 +
<li>R/C: pCerulean_VP1up_NLS_mVenus_VP2/3_HSPG-KO in cotransfection with pSB1C3_001_RC_IRCK_VP1-ko_HSPG-ko_P5tataless cl1</li>
 +
 +
</ul>
 +
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">12.10</th>
 +
<th width="100">13.10</th>
 +
<th width="100">14.10</th>
 +
<th width="100">15.10</th>
 +
<th width="100">16.10</th>
 +
<th width="100">17.10</th>
 +
<th width="100">18.10</th>
 +
<th width="100">19.10</th>
 +
<th width="100">20.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td>-</td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
<b>The results</b>
 +
 +
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">12.10 Seeding AAV293 cells for transfection with mVenus as GOI and CFP_Middlelinker_VP2/3_HSPG-KO</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
This viral stock is for live imaging and probably for western blotting, the ratio of the Rep/Cap plasmids is 1:1.<br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">18.10</th>
 +
<th width="100">19.10</th>
 +
<th width="100">20.10</th>
 +
<th width="100">21.10</th>
 +
<th width="100">22.10</th>
 +
<th width="100">23.10</th>
 +
<th width="100">24.10</th>
 +
<th width="100">25.10</th>
 +
<th width="100">26.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td>-</td>
 +
<td>FACS</td>
 +
</tr>
 +
</table><br />
 +
Transfection was performed according to standard protocol:
 +
<ul>
 +
<li>Gene of interest: mVenus</li>
 +
<li>R/C: CFP_Middlelinker_VP2/3_HSPG-KO in cotransfection with pSB1C3_001_RC_IRCK_P5tataless clone 1</li>
 +
<br />
 +
</ul>
 +
<b>The results</b>
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">17.10 Production of AAV2 with 587-His</p>===
 +
Investigator Patrick <br>
 +
<br>
 +
<b>The motivation</b><br />
 +
We wanted to produce AAV2 which could be purified via affinity purification. Therefore 10 x 10cm^2 were seeded with AAV-293. Five of these plates contained serum-free medium and cells accustomized to this. <br>
 +
Used plasmids:
 +
* pHelper
 +
* pSB1C3_leftITR_CMV_betaglobin_mvenus_hGH_rightITR (P541)
 +
* 50% pSB1C3_001_RC_IRCK_P5tataless (P712)
 +
* 50% pSB1C3-001_pCMV_[AAV2]VP123_587_HIS (P638)
 +
 +
<br />
 +
<b>The plan</b><br />
 +
In this section, the design of the experiment is explained.
 +
<br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">17.10</th>
 +
<th width="100">19.10</th>
 +
<th width="100">20.10</th>
 +
<th width="100">21.10</th>
 +
<th width="100">22.10</th>
 +
<th width="100">23.10</th>
 +
<th width="100">24.10</th>
 +
<th width="100">25.10</th>
 +
<th width="100">26.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>AAV2 harvest</td>
 +
<td>Transduction</td>
 +
<td></td>
 +
<td>FACS</td>
 +
<td></td>
 +
</tr>
 +
</table><br />
 +
 +
<b>The results</b><br />
 +
Interpretation and discussion of our results.
 +
<br />
 +
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">18.10 Seeding AAV293 cells for transfection Superconstructs</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
We want to create a viral stock for purification and biotinylation, the ratio of the Rep/Cap plasmids is 1:1.<br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">18.10</th>
 +
<th width="100">19.10</th>
 +
<th width="100">20.10</th>
 +
<th width="100">21.10</th>
 +
<th width="100">22.10</th>
 +
<th width="100">23.10</th>
 +
<th width="100">24.10</th>
 +
<th width="100">25.10</th>
 +
<th width="100">26.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td>-</td>
 +
<td>FACS</td>
 +
</tr>
 +
</table><br />
 +
Transfection was performed according to standard protocol:<br />
 +
<br />
 +
<b>Gene of interest: CMV_mVenus</b>
 +
<ul>
 +
<li>pSB1C3_CMV_Zegfr:1907_MiddleLinker_VP2/3_587-KO_6xHis in ratio 1:1 pSB1C3_001_RC_IRCK_VP2-ko_HSPG-ko_P5tataless cl1</li>
 +
<li>pSB1C3-001_pCMV_[AAV2]VP123_453_Z34C in ratio 1:1 pSB1C3_001_RC_IRCK_HSPG-ko_P5tataless_RFC10</li>
 +
<li>pSB1C3_001_CMV_VP123_587-KO_Z34C in ratio 1:1 pSB1C3_001_RC_IRCK_HSPG-ko_P5tataless_RFC10</li>
 +
<li> pSB1C3_001_CMV_VP123_587-KO_Z34C_spacer in ratio 1:1 pSB1C3_001_RC_IRCK_HSPG-ko_P5tataless_RFC10</li>
 +
</ul><br />
 +
<b>Gene of interest: pTERT_TKGMK</b>
 +
<ul>
 +
<li>pSB1C3_CMV_Zegfr:1907_MiddleLinker_VP2/3_587-KO_6xHis in ratio 1:1 pSB1C3_001_RC_IRCK_VP2-ko_HSPG-ko_P5tataless cl1</li>
 +
</ul><br />
 +
<b>Gene of interest: CMV_TKGMK</b>
 +
<ul>
 +
<li>pSB1C3_CMV_Zegfr:1907_MiddleLinker_VP2/3_587-KO_6xHis in ratio 1:1 pSB1C3_001_RC_IRCK_VP2-ko_HSPG-ko_P5tataless cl1</li>
 +
</ul><br />
 +
 +
<b>The results</b>
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">18.10 Seeding AAV293 cells for transfection with Cytosindeaminase</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
<br />
 +
We want to create viral stocks with CMV_Cytosindeaminase and pTERT_Cytosindeaminase as gene of interests, to  check qualitatively the bystander effect.<br />
 +
<br /><b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">18.10</th>
 +
<th width="100">19.10</th>
 +
<th width="100">20.10</th>
 +
<th width="100">21.10</th>
 +
<th width="100">22.10</th>
 +
<th width="100">23.10</th>
 +
<th width="100">24.10</th>
 +
<th width="100">25.10</th>
 +
<th width="100">26.10</th>
 +
<th width="100">27.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>seeding AAV293</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Transfection</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Seeding HT</td>
 +
<td>Harvest + Transduction</td>
 +
<td>-</td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
Transfection, harvest and transduction were performed according to standard protocol:<br />
 +
<br />
 +
<b>Gene of interest: CMV_Cytosindeaminase</b>
 +
<ul>
 +
<li>P712</li>
 +
</ul>
 +
<b>Gene of interest: pTERT_Cytosindeaminase</b>
 +
<ul>
 +
<li>P712</li>
 +
</ul>
 +
<br />
 +
 +
<b>The results</b>
 +
 +
===<p style="font-size:17px; background-color:#00dd77;">22.10.2010 Transduction with old mVenus Stocks for taking pictures</p>===
 +
<br />
 +
<b>The motivation</b>
 +
We transduced HT1080 with our stocks packaged with CMV_mVenus.
<br />
<br />
<b>The plan</b><br />
<b>The plan</b><br />
Line 1,274: Line 2,151:
<th width="100">24.9</th>
<th width="100">24.9</th>
<th width="100">25.9</th>
<th width="100">25.9</th>
-
<th width="100">26.9</th>
+
</tr>
-
<th width="100">27.9</th>
+
<tr>
-
<th width="100">28.9</th>
+
<td>Action</td>
-
<th width="100">29.9</th>
+
<td>seeding HT1080</td>
-
<th width="100">30.9</th>
+
<td>Transduction</td>
 +
<td>-</td>
 +
<td>Fluorescence microscopy</td>
 +
</tr>
 +
</table>
 +
<b>The results</b>
 +
 
 +
<gallery widths=300px heights=300px perrow=2 caption="Transduction with vectors pSB1C3_001_RC_IRCK_P5tataless as R/C and CMV_mVenus">
 +
Image:Freiburg10_transduction_CMV_mVenus_1.png|
 +
Image:Freiburg10_transduction_CMV_mVenus_2.png|
 +
Image:Freiburg10_transduction_CMV_mVenus_4.png|
 +
</gallery>
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">23.10 Testing the bystander effect of the cytosine deaminase</p>===
 +
<br />
 +
<b>The motivation</b><br />
 +
<br />
 +
The activated form of 5-fluorocytosine has the ability to diffuse through the plasma membrane. In this way cells get killed which were not transduced by the viral particles. We use an old yfp stock t determine if the transgene expression is on and to harvest the cells which are transduced with cytosine deaminase loaded AAV2.<br />
 +
<br /><b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">23.10</th>
 +
<th width="100">24.10</th>
 +
<th width="100">25.10</th>
 +
<th width="100">26.10</th>
 +
<th width="100">27.10</th>
 +
<th width="100">28.10</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>Transduce HT1080 and seed HT1080</td>
 +
<td>Transfer the transduced HT1080 onto the non transduced HT1080</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>-</td>
 +
<td>Measure living cells via Neubauer cellchamber</td>
 +
</tr>
 +
</table>
 +
<br />
 +
<br />
 +
<b>Gene of interest: CMV_Cytosindeaminase</b>
 +
<ul>
 +
<li>P712</li>
 +
</ul>
 +
<b>Gene of interest: CMV_mVenus</b>
 +
<ul>
 +
<li>P468</li>
 +
</ul>
 +
<br />All dishes had this order:<br />
 +
<br />
 +
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="80"> </th>
 +
<th width="80">1</th>
 +
<th width="80">2</th>
 +
<th width="80">3</th>
 +
 
 +
</tr>
 +
<tr>
 +
<td>A</td>
 +
<td>Medium with prodrug</td>
 +
<td>Medium with prodrug</td>
 +
<td>Medium with prodrug</td>
 +
</tr>
 +
<tr>
 +
<td>B</td>
 +
<td>Medium</td>
 +
<td>Medium</td>
 +
<td>Medium</td>
 +
</tr>
 +
</table>
 +
<br />The concentration of the prodrug 5-fluorocytosine is 54 mmolar<br />
 +
<br />Cells were seeded following this scheme:<br />
 +
<b><font size="3">plate 1</font></b>
 +
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="80"> </th>
 +
<th width="80">1</th>
 +
<th width="80">2</th>
 +
<th width="80">3</th>
 +
 
 +
</tr>
 +
<tr>
 +
<td>A</td>
 +
<td>1*10<sup>5</sup> HT1080 transduced with CMV_Cytosindeaminase</td>
 +
<td>1*10<sup>5</sup> HT1080 transduced with CMV_Cytosindeaminase</td>
 +
<td>1*10<sup>5</sup> HT1080 transduced with CMV_Cytosindeaminase</td>
 +
</tr>
 +
<tr>
 +
<td>B</td>
 +
<td>1*10<sup>5</sup> HT1080 transduced with CMV_Cytosindeaminase</td>
 +
<td>1*10<sup>5</sup> HT1080 transduced with CMV_Cytosindeaminase</td>
 +
<td>1*10<sup>5</sup> HT1080 transduced with CMV_Cytosindeaminase</td>
 +
</tr>
 +
</table>
 +
<br />
 +
 
 +
<br />
 +
<b><font size="3">plate 2</font></b>
 +
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="80"> </th>
 +
<th width="80">1</th>
 +
<th width="80">2</th>
 +
<th width="80">3</th>
 +
 
 +
</tr>
 +
<tr>
 +
<td>A</td>
 +
<td>2*10<sup>5</sup> HT1080 non transduced</td>
 +
<td>2*10<sup>5</sup> HT1080 non transduced</td>
 +
<td>2*10<sup>5</sup> HT1080 non transduced</td>
 +
</tr>
 +
<tr>
 +
<td>B</td>
 +
<td>2*10<sup>5</sup> HT1080 non transduced</td>
 +
<td>2*10<sup>5</sup> HT1080 non transduced</td>
 +
<td>2*10<sup>5</sup> HT1080 non transduced</td>
 +
</tr>
 +
</table>
 +
<br />
 +
The next plates were seeded with non transduced cells and 1*10<sup>5</sup> of the cytosin deaminase transduced cells
 +
<br />
 +
<b><font size="3">plate 3</font></b>
 +
<table border="3" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="80"> </th>
 +
<th width="80">1</th>
 +
<th width="80">2</th>
 +
<th width="80">3</th>
 +
 
 +
</tr>
 +
<tr>
 +
<td>A</td>
 +
<td>2*10<sup>5</sup> HT1080</td>
 +
<td>2*10<sup>5</sup> HT1080</td>
 +
<td>2*10<sup>5</sup> HT1080</td>
 +
</tr>
 +
<tr>
 +
<td>B</td>
 +
<td>2*10<sup>5</sup> HT1080</td>
 +
<td>2*10<sup>5</sup> HT1080</td>
 +
<td>2*10<sup>5</sup> HT1080</td>
 +
</tr>
 +
</table>
 +
 
 +
<b>The results</b>
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">25.10.2010 Transduction with several constructs for Flow Cytometry</p>===
 +
<br />
 +
<b>The motivation</b>
 +
We want to quantify via flow cytometry the Affibody superconstruct, Darpin HSPG-KO Construct and standard R/C with HSPG-KO.
 +
<br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">25</th>
 +
<th width="100">26</th>
 +
<th width="100">27</th>
 +
</tr>
 +
<tr>
 +
<td>Action</td>
 +
<td>Transduction</td>
 +
<td>-</td>
 +
<td>FACS</td>
 +
</tr>
 +
</table>
 +
<b>The results</b>
 +
 
 +
===<p style="font-size:17px; background-color:#00dd77;">BLANK EXPERIMENT</p>===
 +
<br />
 +
<b>The motivation</b>
 +
<br />
 +
<b>The plan</b><br />
 +
<table border="5" rules="all" cellpadding="5" cellspacing="1" style="font-size:13pt;text-align:center" >
 +
<tr>
 +
<th width="100">Days</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
 +
<th width="100">-</th>
</tr>
</tr>
<tr>
<tr>
Line 1,294: Line 2,358:
</table>
</table>
<b>The results</b>
<b>The results</b>
 +
<h1>Citations</h1>
<h1>Citations</h1>

Latest revision as of 21:38, 27 October 2010

=> Back to Notebook overview

NoteBook Navigator

Contents

Cellculture

This subpage is for cellculture, the structure of each experiment is following:

Date of first action, title of the experiment


The motivation
This short introduction provides an inside into our thoughts for this experiment.
The plan
In this section, the design of the experiment is explained.
The results
Interpretation and discussion of our results.



14.6 Seeding AAV293 for transfection


The motivation
We want to create viral stocks with the stratagene R/C, the gene of interest is mVenus. This is a qualitative control.

The plan

Days 14.6 15.6 16.6 17.6 18.6 19.6 20.6 21.6
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction Fluorescence microscopy

AAV 293 and HT1080 Cells have been splitted and plated out on 10 cm dishes for transfektion. After harvesting the cells according to the standard protocol the cell-pellets were resuspendiated in 15ml of DYT medium. 2,5µl of this cell suspension have been mixed with 47.5µl of trypan blue and the cells were counted by using the Neubauer-Meteringchamber.

We counted 12,5x 10^6 cells/ml for the AAV293 cell line and 10x10^6 cells /ml for the HT1080 cell line.

1ml and 1,5 ml of the AAV 293 cells have been seeded on four dishes with 250µl of the cell suspension. Note that that the date is wrong on the plates and the flasks! Cells have been already plated out on the 14th. of June.

We also seated two flasks one for each cell line. Therefor we used 1ml of the HT1080 cell suspension and 2ml of the the AAV293 cells.
1)

  • pAAV_iGEM_mVenus_YFP (glycerol stock B34, P39) P39 has the correct sequence (confirmed)
  • pHelper
  • pAAV_RC

2)

  • pAAV_iGEM_mVenus_YFP (glycerol stock B33, P38) P38 (we dont know if P39 has the correct sequence!)was used because the amount of P39 was not sufficient enough for four Transfections!
  • pHelper
  • pAAV_RC

Plasmid concentrations:
pAAV_RC: 1 µg/µl
pHelper: 280 ng/µl
pAAV_iGEM_mVenus_YFP, P39: 180,83 ng/µl
pAAV_iGEM_mVenus_YFP, P38: 179,75 ng/µl

Cellculture clone 1 and 2 were transfected with P39. Cellculture clone 3 and 4 were transfected with P38.


We could only pipet 3,3 µg (instead of 10 µg) from each of the 3 plasmids into the 15 ml falcons due to insufficient amount of plasmid.

Adrian tried to examine the precipation of the CaCl2+ DNA Clusters. We have to optimize the pH of our 2xHBS at the moment it is 11.12.
The viral stocks were harvested according to standard protocol.
The results

Results of transduction, ~ 1% of the HT1080 showed expression of mVenus.

Bright light image 1

Fluoresce microscopy image 1

Bright light image 1

Fluoresce microscopy image 1


According to the stratagene protocol, transduction efficencies about ~80% are achievable. We performed every step under guidance, so probably something is wrong with the buffers, cells or even the standard protocol. The next step is to repeat this transfection.

19.6 Seeding AAV293 for second transfection according to standard protocol


The motivation
We want to repeat the last transfection and obtain a vsibly higher GOI (mVenus) expression.
The plan

Days 19.6 20.6 20.6 21.6 22.6 23.6 24.6 25.6
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction Fluorescence microscopy

Six transfections were performed according to the standart protocol:
Three 10 cm cellcluture dishes with 293 cells were transfected with 10 µg DNA (3,33 µg each plasmid) and the other three 10 cm cellculture dishes with 30 µg DNA (10 µg DNA each plasmid).

Plasmids:

  • pAAV_iGEM-MCS_mVenus (P41), 507 ng/µl
  • pAAV_RC , 1000 ng/µl
  • pHelper , 280 ng/µl


  • Transduction of 2x6 wells was successfully done (14.25)
  • one six well was transduced with 10µg the other with 30µg DNA amount

The results

Results of transduction nr.2

10µg_unverd_2_(c1).JPG 48h post transduction

10µg_unverd_1_(c1).JPG 48h post transduction

30µg_unverd_2_(c1).JPG 48h post transduction

30µg_unverd_(c1).JPG 48h post transduction

30µg_unverd_4_(c1).JPG 48h post transduction

30µg unverd 3 (c1).JPG 48h post transduction

30µg_unverd_6_(c1).JPG 48h post transduction

30µg_unverd_5_(c1).JPG 48h post transduction, we changed the mVenus-yellow to pink, for the girls :)


The Transduction efficency is still quite low! We have to optimize the stratagene protocol!

30.6 Examination of different Transduction methods


The motivation
We want to check whether the amount of our produced AAV2s has an effect on the transduction rate. Instead of 500µl, 1000µl of the AAV-stock were pipetted into each well.

The plan

Days 30.6 1.7 2.7 3.7 4.7 5.7 6.7 7.7
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction Fluorescence microscopy

1. Plate I(A is up)

3x10^5 cells 3x10^5 cells 3x10^5 cells
3x10^5 cells 3x10^5 cells 3x10^5 cells

Transduction:

1000 µl of Viral Stock DROPPED 1000 µl of Viral Stock gently resuspended1500 µl of Viral Stock rough resuspending
1000 µl of Viral Stock DROPPED 1000 µl of Viral Stock gently resuspended no Transduction


The results
All cells died probably because we forgot to wash the cells with PBS before adding fresh medium. It was not possible to take pictures because the dead cells were all clumped. Looks like we should not transduce 3x10^5 cells with 1000 µl (or more) of our viral solution because almost all cells died in all approaches and the medium indicator was yellow. So we can not say if resuspendig the cells with the viral soultion is a useful alteration of the standard protocol.


3.7 Seeding AAV293 for transfection with different plasmid amounts and harvesting methods


The motivation
We want to check if the amount of plasmids is the reason for the low transduction efficiency. Unfortunately the flow cytometry (FACS) is not available at the moment so the results can only be checked via fuorescence microscopy.

The plan

Days 3.7 4.7 5.7 6.7 7.7 8.7 9.7 10.7
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction Fluorescence microscopy

Transfection with P41 (pAAV_iGEM-MCS_mVenus) was performed according standart protocol. Two transfections where carried out with 10µg (3,33 µg each plasmid) DNA and the other two with 20µg DNA (6,66 µg each plasmid).
We want to investigate which of the following approaches yields a better transduction efficiency.

  • Half of the transfected cells were exposed 3 cycles of thawing and freezing and then centrifuged (15 ml falcon, 2100G). The supernatant was transfered into a new 15 ml falcon and used for transduction.
  • The other half was centrifuged at 300 G for 5min . The supernatant was transfered into another 15 ml falcon and the pellet was resuspended with 5 ml of DMEM. The content of these two falcons was also exposed to 3 cycles of thawing and freezing and then used for transduction.
  • We have got 2 10 cm cellculture dishes with 10µg and 2 dishes with 20µg DNA used for transfection.

Approach with standart protocol (one dish with 10 and the other with 20µg Plasmids)(2100 G and 3 cycles of freezing and thawing)

Deviations from the standart protocol:

  • The cells were centrifuged at 2100 G instead of 10.000 G
  • The viruses were harvested after 44 hours
  • 3 cycles of freezing and thawing


  • used plasmids: 10µg, 20µg GOI-plasmid (mVenus)
  • we have 10µg and 20µg from standart protocol => standard virus
  • we have 10µg and 20µg from standart protocol pellet => Pellet
  • we have 10µg and 20µg from standart protocol suspension => Super
  • amount of 500µl

1. Plate I(A is up)

10µg dropped Super 10µg dropped Super gently resuspending10µg dropped Super gently resuspending
10µg Super gently resuspending Super20µg dropped Super gently resuspending 1:10 dilution control


2. Plate I(A is up)

10µg dropped Super 10µg dropped Super gently resuspending10µg dropped Super gently resuspending
10µg Super gently resuspending Super20µg dropped Super gently resuspending 1:10 dilution control


3. Plate I(A is up)

10µg dropped Pellet 10µg dropped Pellet gently resuspending10µg dropped Pellet gently resuspending
10µg Super gently resuspending Pellet20µg dropped Pellet gently resuspending 1:10 dilution control



The results

Results of transduction with different harvested viral particles

plate 1 A 1

plate 1 A 2


We only took some pictures from single cells, because there was no significant difference in fluorescence between each sample. The main conclusion of this experiment is, that we have to get the flow cytometry started.

4.7 Transfection with different amounts of plasmids


The motivation
We want to check if the mVenus expression and transduction efficiency can be improved with higher amounts of DNA.

The plan

Days 4.7 5.7 6.7 7.7 8.7 9.7 10.7 11.7
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS

The Transfection was performed with 10, 18 and 24 µg per plasmid (mVenus, pHelper and R/C).
The virus harvest was performed according to standard protocol:

  • 3 Plates got transduced

1. Plate I(A is up) completely 10 µg

300µl resuspended300µl resuspended450µl resuspended
600µl resuspended600µl resuspended control


2. Plate II(A is up)completely 18 µg

300µl resuspended300µl resuspended450µl resuspended
600µl resuspended600µl resuspended control


3. Plate III(A is up) completely 24 µg

300µl resuspended300µl resuspended450µl resuspended
600µl resuspended600µl resuspended control

The results
FACS analysis of different treated HT1080 cells was done (18 samples)

The first percentage refers to the living and fluorescent cells and the second percentage to the total amout of living cells.

The data are listed this way:

1. Plate I(A is up)

A1A2A3
B1B2B3

1= Plate 1 A1 : 0% YFP-positive Cells (there were only a few cells in this sample)
2= Plate 1 A2 : 27,7% YFP-positve Cells from 73,3%
3= Plate 1 A3 : 17,3% " from 63,1%
4= Plate 2 A1 : 32,9% " from 75,3%
5= Plate 2 A2 : 27,2% " from 76,5%
6= Plate 2 A3 : 30,7% " from 73,4%
7= Plate 3 A1 : 26,8% " from 76,0%
8= Plate 3 A2 : 30,5% " from 74,2%
9= Plate 3 A3 : 30,7% " from 75,2%
10= Plate 1 B1 : 6,25% " from 36,1%
11= Plate 1 B2 : 6,42% " from 68,4%
12= Plate 1 B3 : 0,05% " from 89,5%
13= Plate 2 B1 : 20,5% " from 72,5%
14= Plate 2 B2 : 15,7% " from 73,6%
15= Plate 2 B3 : 0,02% " from 85,4%
16= Plate 3 B1 : 19,5% " from 73,3%
17= Plate 3 B2 : 20,8% " from 75,7%
18= Plate 3 B3 : 0,07% " from 84,8%


Conclusions

  • Higher amounts of Plasmids (24, 30µg) seems to have no obvious effect on YFP expression
  • Theres no difference in YFP expression comparing resuspended samples to not resuspended samples
  • The amount of dead HT cells is about 25%, it is not clear if it is either AAV induced or mechanic stress (Trypsin, washing procedure)

Next steps:

  • does the amount of GOI (ng plasmids) has an effect on YFP expression
  • compare transduced to non transduced cells (vitality), or in other words is the mechanic stress responsible for 25% dead cell ratio?
  • comparison of transduction efficiency of different virus stock production routines


14.7 Seeding AAV293 for TKGMK constructs


The motivation
We want to create the first viral particles with TKGMK as gene of interest.

The plan

Days 14.7 15.7 16.7 17.7 18.7 19.7 20.7 21.7
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS

30µg Plasmid were used (pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30)
VIRUS no GOI :pHelper + pAAV_RC
VIRUS 1  :pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30 clone 1 : P54
VIRUS 2  :pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30 clone 2 : P55
VIRUS 3  :pHelper + pAAV_RC+ pAAV_RFC25_mgmk_TK30 clone 3 : P56


The results
Unfortunately the stocks never were used (exception: see following experiment, 7. august) because later on we noticed that the TKGMK plasmids were not in line with the RFC.



7.8 Seeding AAV293 for TKGMK and mVenus stocks

The motivation After proofing the successfull transduction of tumor cells with the reportergen mVenus the next step is to kill the cells with a prodrug approach. The prodrug of our choice is the guanosine anolog ganciclovir, once activated ganciclovir gets integrated into the growing dna chain which results in termination of dna synthesis and cell death. We transduce the tumor cell line HT1080 with viral particles packed with the thymidine kinase guanosine mono phosphate kinase fusion protein (TKGMK) as gene of interest and the incubation with ganciclovir should kill the cells.

The plan

Days 7.8 8.8 9.8 10.8 11.8 12.8 13.8 14.8
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS and microscopy


Plate pAAV_RC/µgpHelper/µgGOI/µg
13,3 3,3 no GOI
26,6 3,3 no GOI
33,3 3,3 3,3 TK_GMK clone1 (P54)
43,3 3,3 3,3 TK_GMK clone1 (P54)
53,3 3,3 3,3 TK_GMK clone2 (P55)
63,3 3,3 3,3 YFP
73,3 3,3 10 YFP
83,3 3,3 20 YFP
93,3 3,3 40 YFP
103,3 3,3 60 YFP


The transduction was performed according to standard protocol.

Plate 1:

1 2 3
A control, no cells 300µl virus 1 300µl virus 2
B control, no virus 600µl virus 1 600µl virus 2


Plate 2:

1 2 3
A control, no cells 300µl virus 3 300µl virus 4
B control, no virus 600µl virus 3 600µl virus 4


Plate 3:

1 2 3
A control, no cells 300µl virus 5 300µl virus 6
B control, no virus 600µl virus 5 600µl virus 6


Plate 4:

1 2 3
A control, no cells 300µl virus 7 300µl virus 8
B control, no virus 600µl virus 7 600µl virus 8


Plate 5:

1 2 3
A control, no cells 300µl virus 9 300µl virus 10
B control, no virus 600µl virus 9 600µl virus 10


Plate 6:

1 2 3
A control, no cells 300µl virus 3 300µl virus 4
B control, no virus 600µl virus 3 600µl virus 4


Plate 7:

1 2 3
A control, no cells 300µl virus 3 300µl virus 4
B control, no virus 500µl virus 3 500µl virus 4


Plate 8:

1 2 3
A control, no cells 300µl virus 5 300µl virus 5
B control, no virus 600µl virus 5 600µl virus 5


The test for functionality for TK GMK was done with the Prodrug Cymeven ganciclovir 500mg from Roche. The final concentration was 0,05 mM in the wells. After two days pictures were taken.




The results

Death to HT1080

HT1080 with gancliclovir only

HT1080 with TK_GMK without ganciclovir

HT1080 with TK_GMK (300µl AAV stock) with ganciclovir

HT1080 with TK_GMK (600µl AAV stock) with ganciclovir

picture from the 40µg stock

As you can see, the TKGMK cell killing mechanism works! The samples with targeted mVenus constructs couldnt be checked because the FACS machine was not working. The fluorescence was checked with microscopy, the transduction efficiency is still low.

14.8 Seeding different amounts of AAV293 for transfection

The motivation
We want to know which confluence of AAV293 cells is optimal for AAV production.

The plan

Days 14.8 15.8 16.8 17.8 18.8 19.8 20.8 21.8
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS


We seed different amounts of cells in 10 cm2, and check the highest titer.

Plate amount of seeded AAV-293 cells
1100 000
2200 000
3400 000
4500 000
5800 000
61 000 000
71 200 000
81 500 000
91 750 000
101 750 000

The cells were transfected with 40µg standard CMV_YFP, 3,3µg Rep/Cap and 3,3µg pHelper.

Transduction was performed according to standard protocol.
Plate 1 YFP: 200.000 cells per well

1 2 3
A control, no cells 165µl virus (1) 165µl virus (2)
B control, no virus 165µl virus (1) 165µl virus (2)

Plate 2 YFP: 200.000 cells per well

1 2 3
A control, no cells 165µl virus (3) 165µl virus (4)
B control, no virus 165µl virus (3) 165µl virus (4)

Plate 3 YFP: 200.000 cells per well

1 2 3
A control, no cells 165µl virus (5) 165µl virus (6)
B control, no virus 165µl virus (5) 165µl virus (6)

Plate 4 YFP: 200.000 cells per well

1 2 3
A control, no cells 165µl virus (7) 165µl virus (8)
B control, no virus 165µl virus (7) 165µl virus (8)

Plate 5 YFP: 200.000 cells per well

1 2 3
A control, no cells 165µl virus (9) 165µl virus (10)
B control, no virus 165µl virus (9) 165µl virus (10)

The results
The FACS was still not available but we could easily detect a significant higher YFP expression (70-80%) at the following positions:

  • Plate 1: A2 and B2, A3 and B3
  • Plate 2: A2 and B2, A3 and B3

Therefore we conclude that we have to seed between 100000 and 500000 cells for optimal virus production precedure.

17.8 transduction with viral stocks 20 µg and 40 µg GOI-plasmid

The Motivation
We want to FACS our stocks to get valid data for further investigation of optimal virus assembly. Therefore created stocks with 20 and 40 µg CMV_mVenus.
The Plan

Days 17.8 18.8 19.8 20.8 21.8 22.8 23.8 24.8
Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS


  • 1. plate 50.000 cells, YFP
    A control no cells 300 µl virus (40 µg YFP) 300 µl virus (20 µg YFP)
    B control no virus 500µl P38 (pAAV2_mVenus) 1000µl P38 (pAAV2_mVenus)
  • 2. plate 50.000 cells, YFP
    A control no cells 300 µl virus (40 µg YFP) 300 µl virus (20 µg YFP)
    B control no virus 500µl P38 (pAAV2_mVenus) 1000µl P38 (pAAV2_mVenus)
  • 3. plate 100.000 cells, YFP
    A control no cells 300 µl virus (40 µg YFP) 300 µl virus (20 µg YFP)
    B control no virus 500µl P38 (pAAV2_mVenus) 1000µl P38 (pAAV2_mVenus)
  • 4. plate 100.000 cells, YFP
    A control no cells 300 µl virus (40 µg YFP) 300 µl virus (20 µg YFP)
    B control no virus 500µl P38 (pAAV2_mVenus) 1000µl P38 (pAAV2_mVenus)

    The Results
    Although we were told that the FACS would be available in time it wasn't. So the cells could unfortunately not be checked for their YFP expression =(.

    16.8 Seeding AAV293 for transfection with new R/C

    The motivation
    We want examine the functionality of different R/C constructs and the new eGFP gene of interest. This transfection was performed with new AAV-293 cells which were thawed.


    The plan

    Days 16.8 17.8 18.8 19.8 20.8 21.8 22.8 23.8
    Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS
    • 2x106 cells were seeded
    • used plasmids:
      • P50 c= 429 ng/µl (RC)
      • P64 c= 500 ng/µl (pHelper)
      • P229 c= 162 ng/µl (GOI=YFP)
      • P228 c= 540 ng/µl (GOI=eGFP)
      • P158a c= 1800ng/µl (RC mutant)
      • P158a c= 1770ng/µl (RC mutant)

    The transfection was performed according to standard protocol.

    • 1. plate: Lipo-Transfection => named Lipo
    • 2. plate: Lipo-Transfection => named Lipo
    • 3. plate: 3,3 µg (RC), 3,3 µg (pHelper), 3,3 µg (YFP) => was not used for transduction
    • 4. plate: 10 µg (RC), 10 µg (pHelper), 3,3 µg (YFP) => named CaCl2
    • 5. plate: 10 µg (RC mutant P158a), 10 µg (pHelper), 3,3 µg (YFP)=> CaCl2 10 µg RC mutant P158a
    • 6. plate: 10 µg (RC mutant P158b), 10 µg (pHelper), 3,3 µg (YFP)=> CaCl2 10 µg RC mutant P158b
    • 7. plate: 3,3 µg (RC mutant P158a), 3,3 µg (pHelper), 3,3 µg (YFP)=> CaCl2 3,3 µg RC mutant P158a
    • 8. plate: 3,3 µg (RC mutant P158b), 3,3 µg (pHelper), 3,3 µg (YFP)=> CaCl2 3,3 µg RC mutant P158b
    • 9. plate: 10 µg (RC), 10 µg (pHelper), 3,3 µg (eGFP)=> CaCl2 eGFP 3,3 µg
    • 10. plate: 10 µg (RC), 10 µg (pHelper), 10 µg (eGFP)=> CaCl2 eGFP 10 µg
    • 11. plate: 10 µg (RC), 10 µg (pHelper), 20 µg (eGFP)=> CaCl2 eGFP 20 µg
    • 12. plate: 10 µg (RC), 10 µg (pHelper), 40 µg (eGFP)=> CaCl2 eGFP 40 µg

    The results

    Freiburg10 23.8.2010 FACS eGFP Lipofection 200.000.jpg

    As you can see the eGFP constructs worked very well. And even the transduction efficiency of the standard R/C is ok, the conclusion is that in previous transfections the AAV293 cells were to confluent so their transfection capability. The confluence of the cells is crucial! It also seems that our used amounts of plasmids had no decisive effect on the YFP expression because of the obviously variating results. A final conclusion is still due.

    19.8 Seeding AAv293 for transfection with different HBS buffers

    The Motivation
    We want to try different 2xHBS Buffers (pH) and their influence on transfection efficiency!

    The Plan

    Days 19.8 20.8 21.8 22.8 23.8 24.8 25.8 26.8
    Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS

    We try 5 different 2xHBS buffers:

    • pH: 7.06
    • pH: 7.08
    • pH: 7.10
    • pH: 7.12
    • pH: 7.14


    Used Plasmids: 10µg of each plasmid

    • GOI: mVENUS => P262, conc:1148ng/µl; used amount: 8,71µl
    • GOI: TKGMK => P82b, conc:1500ng/µl; used amount: 6,67µl
    • pHELPER => P64, conc:503ng/µl; used amount: 20µl
    • RepCap => 10.8: 1348ng/µl; used amount: 7,41µl


    • Transduction of three 6-well plates:

    Plate 1 YFP: 150.000 cells per well

    1 2 3
    A control, no cells 500µl virus (1) 500µl virus (2)
    B control, no virus 500µl virus (1) 500µl virus (2)

    Plate 2 YFP: 150.000 cells per well

    1 2 3
    A control, no cells 500µl virus (3) 500µl virus (4)
    B control, no virus 500µl virus (3) 500µl virus (4)

    Plate 3 YFP: 200.000 cells per well

    1 2 3
    A control, no cells 500µl virus (5) 500µl virus (9)
    B control, no virus 500µl virus (9) 500µl virus (5)


    • (1)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,06
    • (2)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,08
    • (3)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,112
    • (4)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,12
    • (5)= 10µg RC, 10µg pHelper, 10µg GOI (YFP); pH(2xHBS)=7,14


    the Results
    AAV-Harvesting is at 24.8, same day Transduction and FACS will be done at 26.8

    Freiburg10 CC 26.8 different HBS.jpg

    As you can see the 2xHBS with pH 7.112 performed best, in future experiments this buffer will be used.

    22.8: Transfection of AAV293 with different amounts of cells, and two plasmid concentrations

    The motivation

    We want to define the final amount of AAV293 per 10 cm2 for optimal AAV-Production

    The plan

    Days 22.8 23.8 24.8 25.8 26.8 27.8 28.8 29.8 30.8
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS

    The following amount of cells were seeded in 10 cm2:

    1. 100.000
    2. 100.000
    3. 200.000
    4. 200.000
    5. 300.000
    6. 300.000
    7. 400.000
    8. 400.000
    9. 500.000
    10. 500.000
    11. 600.000
    12. 600.000
    13. 700.000
    14. 700.000


    10µg RC P158a four times mutant, 10µg pHelper, 3,3 µg mVenus P162 were pipetted on plates: 2, 4, 6, 8, 10 , 12, 14
    3,3µg RC P158a four times mutant, 3,3µg pHelper, 3,3 µg mVenus P262 were pipetted on plates: 1, 3, 5, 7, 9, 11, 13


    The results

    Freiburg10 30.2010 FACS number of Cells and Beas construct.jpg

    There is only one value for each approach but nevertheless the average YFP expression should be higher. We really dont know the reason for the quite low YFP expression. There are also very good news: the reassembled construct (pSB1C3_leftITR_CMV_betaglobin_mVenus_hGH_rightITR) created from the single Biobricks works as "well" as the AAV2 with CMV_mVenus!



    30.8 Seeding AAV293 for Transfection of 10 cm2 plates


    The motivation
    We want to create ten hypothetical identical viral stocks to estimate the standard deviation.

    The plan

    Days 30.8 31.8 1.9 2.9 3.9 4.9 5.9 6.9
    Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS


    Transfection will be done with:

    • RepCap:P357 10µg =>conc.:1274,8ng/µl used amount: 7,84µl
    • pHelper:P356 10µg =>conc.:1068ng/µl used amount: 9,36µl
    • mVenus:P261 => excel sheet P263: 10µg =>conc.:979ng/µl used amount: 10,21 µl


    0,5 ml of each stock be stored at -80°C.

    9,5 ml of each stock will be used for Transduction.

    Result:
    Freiburg10 Unbenannt.jpg
    Standard deviation: about +/- 4,98% YFP expression. All future AAV2 stocks will be pooled if produced with this same plasmids and amounts of plasmids. Unfortunately the YFP expression is still located at around 50%. We would like to have a YFP expression of at least 70% because as soon as we start to test our not yet ready modified AAV2 we suggest the YFP expression will obviously decrease.



    4.9 Seeding cells for checking constructs (GOIs) with/without HGH and beta globin and reassembled as control


    The motivation
    We want to check the functionality of these genes of interest

    The plan

    Days 4.9 6.9 7.9 8.9 9.9 10.9 11.9 12.9
    Action seeding AAV293 - Transfection - Seeding HT Harvest + Transduction FACS
    • P269 pSB1C3_lITR_CMV_beta-globin_mVenus_HGH_rITR = 325 ng/µl => 9,66 µl
    • P270 pSB1C3_lITR_CMV_beta-globin_mVenus_HGH_rITR = 561 ng/µl => 7,26 µl
    • P377 pSB1C3_lITR_CMV_mVenus_HGH_rITR = 325,04 ng/µl => 30,76 µl
    • P378 pSB1C3_lITR_CMV_beta-globin_mVenus_rITR = 561 ng/µl => 17,8µl

    Additionally P50: pAAV_RC R/C (26,45 µl) and pHELPER (14,61µl) pipetted to each approach.


    The results

    6.9 checking five ganciclovir concentrations for two day incubation approach optimal medication


    The motivation
    We want to check the optimal ganciclovir concentration, we use the TK/GMK Stocks (10 µg from each plasmid) from 24.8 with Buffer pH 7,10 and the pH12 stock.

    The plan

    Days 3.9 4.9 5.9 6.9
    Action seeding HT Transduction - FACS


    We want to use five different ganciclovir concentrations (the concentrations are absolute to the volume in the wells):

    • 48.5µM
    • 97 µM
    • 0.485 mM
    • 0.97 mM
    • 4.85 mM


    the results

    Freiburg10 CC 6.9 Checking Ganciclovir concentrations-CHART.jpg


    As expected the highest concentration of ganciclovir worked the best but it is remarkable that there is no significant difference between the first three ganciclovir amounts. The most remarkable note is, that in future experiments the incubation time has to be extended to 3 or 4 days.

    15.9 Seeding AAV293 for testing our Affibody and other VP-mVenus constructs


    The motivation
    The pCerulean_VP1up_mVenus_Vp2/3 Construct will be tested in three different compositions.

    The plan
    We want to test these constructs:

    • pCerulean_VP1up_NLS_Affibody_VP2/3
    • pCerulean_VP1up_His_VP2/3
    • pCerulean_VP1up_mVenus_Vp2/3

    The His-tag is for purify our constructs and in this case we want to test, if the particles are still infectious. Construct with the affibody will be tested for functionality and even for their better affinity to our EGFR overexpressing cell line A431.


    The results
    Interpretation and discussion of our results.

    19.9 Seeding AAV293 for checking two different Rep/Cap Constructs


    The motivation
    During the project 22 silent nucleotide exchange mutations were introduced into the capsid coding construct to make it compatible with the RFC standards and to have single cutting restriction enzymes flanking the 453 and the 587 loop sequence. Two point mutations had to be dismissed, because either a first test transduction showed that the construct was not working anymore or the insertion of the synthesized gene posed serious problems, because the restriction enzyme did not work.
    The plan
    Transfection and transduction was performed according to standard protocol.


    The results
    Freiburg10 CC 19.9 FACS Checking functionality of REP CAP.jpg

    Finally, we have a construct that is shown to produce infectious particles comparable to the current AAV systems and carries 20 point mutations. Now we can announce that the Adeno-associated Virus is compatible to the RFC standard and the idea to replace the loop sequences via ViralBricks works!



    22.9 Seeding AAV293 for transfection with different mVenus constructs for checking specific promoter activity


    The motivation
    We want to check if the CMV and pTERT promoters work equaly in the AAV293, A431 and HT1080 cells. So we transfect them via standard transfection CaCl2. It is obvious that the individual cell lines are not equaliy competent to transfection (the AAV293 are optimised for transfection). It seems that this promoter is not that active in AAV293 cells.
    The plan
    We transfected the three cell lines A431, AAV293 and HT1080 with following three constructs:

    • CMV_mVenus
    • CMV_eGFP
    • pTERT_mVenus


    Remember, that mVenus and eGFP have the exact same excitation wavelenght. We took the pictures with the same parameters, but saved the data in the wrong formate (.tif instead of .zvi), so we werent able to change the YFP expression from green to yellow.


    Days 22.9 23.9 24.10 25.10 26.10
    Action seeding AAV293 - Transfection fluorescence microscopy fluorescence microscopy


    Transfection of different cell types with different promoter_reportergenes

    AAV293 CMV_eGFP 16h post transfection

    AAV293 CMV_mVenus 16h post transfection

    AAV293 pTERT_mVenus 16h post transfection

    AAV293 CMV_eGFP 48h post transfection

    HT1080 CMV_mVenus 48h post transfection

    A431 CMV_mVenus 48h post transfection


    The results
    As excepted, the expression of the CMV_mVenus and CMV_eGFP was very high even at 16h post transfection. The pTERT_mVenus construct worked aswell, but significantly weaker! Problematic is the fact, that there was no expression in HT1080 and A431 detectable. Due the fact that these cell lines are not optimized for CaCl2 transfection. We can't evaluate if the bad transfection efficiency or the low promoter activity of pTERT are responsible for the results.

    22.9 Testing of Hannas 6 VP-constructs with different compositions (10%, 25%, 50% and 75% fractions) with a VP2-knockout construct


    The motivation
    Test the following 18 constructs for functionality on A431 and HT1080 cells. Each of these constructs getting transfected in different compositions 25%, 50%, 75% and 90% with VP2_knockout 75%. In this way we are able to create viral particles with this ratios of VP proteins. We hope that the created particles are still infectious.

    • pCerulean_CFP_MiddleLinker_VP2/3insCap P528
    • pCerulean_Zegfr:1907_ShortlLinker_VP2/3insCap P527
    • pCerulean_6xHis_Middlelinker_VP2/3insCap P534
    • pCerulean_Zegfr:1907_Middlelinker_VP2/3insCap P535
    • pCerulean_Zegfr:1907_SEG_VP2/3_Capins 10:90 P502
    • pCerulean_Zegfr:1907_LongLinker_VP2/3_CapIns P503


    The plan

    Days 20.9 21.9 22.9 23.9 24.9 25.9 26.9 27.9 28.9
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS


    The results
    Freiburg 10 FACS Linker Libary.jpg
    Obviously the constructs still work!

    22.9 Seeding cells for testing pTERT_mVenus in R/C P326 and P431


    The motivation
    We want to check if the pTERT-promoter is realiable for tumor specific gene expression, we use two different kinds of R/C.

    The plan

    Days 22.9 23.9 24.9 25.9 26.9 27.9 28.9 29.9 30.9 1.10 2.10 3.10 4.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest - - Seeding HT, A293 and A431 Transduction FACS


    The results

    29.9 Checking location of VP proteins via fluorescence microscopy and checking fractions of centrifugation steps via fluorescence spectrometer


    The motivation: We want to figure out if it is possible to purify our viral stocks via centrifugation with 10.000 g and/or 20.000 g. In theory/ according to the literature the viral particles should be in the cells and attached to the HSPGs at the cellular surfaces.
    The plan: Two different viral stocks were prepared:

    Stock 1 with VP2-mVenus-fusion-Capsid loaded with TKGMK (4 wells from a 6 well plate)

    • R/C 1: 50% pCerulean_VP1up_NLS_mVenus_Vp2/3 P501
    • R/C 2: 50% Rep/Cap2: P449 pAAV_RC_4fachmut_VP1-ko:
    • GOI: TKGMK: P82.b
    • pHelper


    Stock 2 "standard" virus (4 wells from a 6 well plate)

    • R/C 1 P486
    • GOI: TKGMK: P82.b
    • pHelper

    These two stocks got harvested according to standard protocol (scratching cells, transfer them in to 15 ml falcons, resuling 12ml solution total). After centrifugation (10 min 200g), the supernatant got transferred into two new 15 ml falcons and the pellets were resuspended with 10 ml DMEM Medium. The Stocks got freezed thawed two times so finally there were:

    1. DMEM as negative control
    2. resuspended Pellet with mVenus-fusioned viral capsids
    3. resuspended Pellet with "standard virus"
    4. supernatant with mVenus-fusioned viral capsids
    5. supernatant with "standard virus"


    The fluorescence of each stock was measured via spectrometer. After that, stocks 2 and 4 were centrifugated 10min with 10.000 g followed by an other fluorescence measuring. Finally the stocks got spin down with 20.000 g for 10 min
    The results:

    Transfection with VP-mVenus-fusion constructs

    Picture two days post transfection.



    Freiburg10 mVenus VP fusion fluorescence centrifugation experiment graph.jpg


    Freiburg10 mVenus VP fusion fluorescence centrifugation experiment 526nm.jpg


    The conclusions: The highest amount of fluorescence was measured in the supernatant, the individual centrifugation steps had no decrease in fluorescence as consequence!


    Keep in mind, without further investigation it is not valid to say that we can purify our stocks via 10-20.000 g centrifugation steps, because we dont know if the viral capsids are still intact! The FACS analysis are not sufficient enough to make a decision, because our last samples had YFP as GOI (=> so efficient cell sorting was not possible). We need to do qPCRs to make a valid evidence.

    30.9 Production of new Standard mVenus Vector


    The motivation
    The AAV2 with 4 point mutations, inserted rep and cap and remutated KpnI restriction has to be checked for its functionality in order to compare it with the wild type AAV2. Hopefully there will be no significant difference.
    The plan
    After the "delay" 200.000 A431 and HT1080 cells were seeded and transduced on the following day with 0,5 ml of this AAV2 mutant.

    Days 30.9 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest delayed because of cell death delayed because of cell death


    The results
    The stocks were harvested successfully

    30.9 Seeding AAV293 for production of standard TKGMK vector


    The motivation
    We want to create a big amount of viral particles with TKGMK as gene of interest for using it as an standard vector for the MTT-assay.
    The plan


    Days 30.9 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest delayed because of cell death delayed because of cell death


    The results
    The viral stocks were harvested efficiently and are ready to use.

    30.9 Seeding AAV293 for production of vectors with mVenus missing beta globin


    The motivation
    Beta globin is said to improve (stratagene) the expression so we expect a worse mVenus (reportergene) expression compared to the standard AAVs. Therefore the seeded A431 and HT1080 cells were transduced with a AAV2 mutant missing beta-globin.
    The plan
    Ater the "delay" 200.000 HT1080 and A431 cells were seeded and transduced with 0,5 ml AAV2 mutant on the following day.

    Days 30.9 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest delayed because of cell death delayed because of cell death


    The results
    Interpretation and discussion of our results.

    30.9 Seeding AAV293 for production of vectors with mVenus missing HGH


    The motivation
    HGH is responsible for the mRNA polyadenylation of the virus so we expect expect a worse mVenus (reportergene) expression compared to the standard AAVs. Therefore the seeded A431 and HT1080 cells were transduced with a AAV2 mutant missing HGH.
    The plan
    After the "delay" 200.000 A431 and HT1080 cells were seeded and transduced on the following day with 0,5 ml AAV2 mutant missing HGH.

    Days 30.9 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest delayed because of cell death delayed because of cell death


    The results
    Interpretation and discussion of our results.

    30.9 Seeding AAV293 for testing RC with HSPG knockout for functionality


    The motivation
    The primary AAV2 receptor (the HSPG receptor) was knocked out so we expect a worse tranduction rate (about 0,3 to 0,4 of the standard transduction rate, assuming that there are HSPGs on the HT1080 and A431 cell surface). The worse the better.
    The plan
    After the "delay" 200.000 A431 and HT1080 cells were seeded and transduced on the following day with 0,5 ml AAV2 mutant with a HSPG-receptor knockout.

    Days 30.9 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest delayed because of cell death delayed because of cell death


    The results

    Freiburg10 HT1080 missing HSPG binding motif.png
    Freiburg10 A431 missing HSPG binding motif.png


    There is a significant difference in transduction efficiency. The actual reduction is even higher than expected, according to literature it should be around 60%, we reached 80%. We measured via qPCR the amount of viral particles for each stock, and they are nearly the same the HSPG Knockout has 2*107particles per ml , the stock with HSPG-binding motif has 4.5*106 particles per ml.

    30.9 Seeding AAV293 for testing RC WITHOUT HSPG knockout for functionality


    The motivation
    The produced vector has the intact HSPG-binding motif, so we can compare it with the vector produced in: "Seeding AAV293 for testing RC with HSPG knockout for functionality"
    The plan
    Transfection and transduction were performed according to standard protocol.

    Days 30.9 1.10 2.10 3.10 4.10 5.10 6.10 7.10 8.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest delayed because of cell death delayed because of cell death


    The results
    See 30.9 Seeding AAV293 for testing RC with HSPG knockout for functionality

    12.10 Seeding AAV293 cells for transfection with VP-BAP


    The motivation
    We want to create a viral stock for purification and biotinylation, the ratio of the Rep/Cap plasmids is 1:1.
    The plan
    Transfection was performed according to standard protocol:

    • Gene of interest: mVenus
    • R/C: pSB1C3-001_pCMV_[AAV]VP123_587_BAP in cotransfection with pSB1C3_001_RC_IRCK_P5tataless clone 1
    Days 12.10 13.10 14.10 15.10 16.10 17.10 18.10 19.10 20.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS

    The results

    12.10 Seeding AAV293 cells for transfection with mVenus as gene of interest and pCerulean_VP1up_NLS_mVenus_VP2/3_HSPG-KO


    The motivation
    We want to create a viral stock for purification and biotinylation, the ratio of the Rep/Cap plasmids is 1:1.
    The plan
    Transfection was performed according to standard protocol:

    • Gene of interest: mVenus
    • R/C: pCerulean_VP1up_NLS_mVenus_VP2/3_HSPG-KO in cotransfection with pSB1C3_001_RC_IRCK_VP1-ko_HSPG-ko_P5tataless cl1
    Days 12.10 13.10 14.10 15.10 16.10 17.10 18.10 19.10 20.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS

    The results


    12.10 Seeding AAV293 cells for transfection with mVenus as GOI and CFP_Middlelinker_VP2/3_HSPG-KO


    The motivation
    This viral stock is for live imaging and probably for western blotting, the ratio of the Rep/Cap plasmids is 1:1.
    The plan

    Days 18.10 19.10 20.10 21.10 22.10 23.10 24.10 25.10 26.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS

    Transfection was performed according to standard protocol:

    • Gene of interest: mVenus
    • R/C: CFP_Middlelinker_VP2/3_HSPG-KO in cotransfection with pSB1C3_001_RC_IRCK_P5tataless clone 1


    The results

    17.10 Production of AAV2 with 587-His

    Investigator Patrick

    The motivation
    We wanted to produce AAV2 which could be purified via affinity purification. Therefore 10 x 10cm^2 were seeded with AAV-293. Five of these plates contained serum-free medium and cells accustomized to this.
    Used plasmids:

    • pHelper
    • pSB1C3_leftITR_CMV_betaglobin_mvenus_hGH_rightITR (P541)
    • 50% pSB1C3_001_RC_IRCK_P5tataless (P712)
    • 50% pSB1C3-001_pCMV_[AAV2]VP123_587_HIS (P638)


    The plan
    In this section, the design of the experiment is explained.

    Days 17.10 19.10 20.10 21.10 22.10 23.10 24.10 25.10 26.10
    Action seeding AAV293 Transfection - Seeding HT AAV2 harvest Transduction FACS

    The results
    Interpretation and discussion of our results.


    18.10 Seeding AAV293 cells for transfection Superconstructs


    The motivation
    We want to create a viral stock for purification and biotinylation, the ratio of the Rep/Cap plasmids is 1:1.
    The plan

    Days 18.10 19.10 20.10 21.10 22.10 23.10 24.10 25.10 26.10
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS

    Transfection was performed according to standard protocol:

    Gene of interest: CMV_mVenus

    • pSB1C3_CMV_Zegfr:1907_MiddleLinker_VP2/3_587-KO_6xHis in ratio 1:1 pSB1C3_001_RC_IRCK_VP2-ko_HSPG-ko_P5tataless cl1
    • pSB1C3-001_pCMV_[AAV2]VP123_453_Z34C in ratio 1:1 pSB1C3_001_RC_IRCK_HSPG-ko_P5tataless_RFC10
    • pSB1C3_001_CMV_VP123_587-KO_Z34C in ratio 1:1 pSB1C3_001_RC_IRCK_HSPG-ko_P5tataless_RFC10
    • pSB1C3_001_CMV_VP123_587-KO_Z34C_spacer in ratio 1:1 pSB1C3_001_RC_IRCK_HSPG-ko_P5tataless_RFC10

    Gene of interest: pTERT_TKGMK

    • pSB1C3_CMV_Zegfr:1907_MiddleLinker_VP2/3_587-KO_6xHis in ratio 1:1 pSB1C3_001_RC_IRCK_VP2-ko_HSPG-ko_P5tataless cl1

    Gene of interest: CMV_TKGMK

    • pSB1C3_CMV_Zegfr:1907_MiddleLinker_VP2/3_587-KO_6xHis in ratio 1:1 pSB1C3_001_RC_IRCK_VP2-ko_HSPG-ko_P5tataless cl1

    The results

    18.10 Seeding AAV293 cells for transfection with Cytosindeaminase


    The motivation

    We want to create viral stocks with CMV_Cytosindeaminase and pTERT_Cytosindeaminase as gene of interests, to check qualitatively the bystander effect.

    The plan

    Days 18.10 19.10 20.10 21.10 22.10 23.10 24.10 25.10 26.10 27.10
    Action seeding AAV293 - - Transfection - - Seeding HT Harvest + Transduction - FACS

    Transfection, harvest and transduction were performed according to standard protocol:

    Gene of interest: CMV_Cytosindeaminase

    • P712

    Gene of interest: pTERT_Cytosindeaminase

    • P712


    The results

    22.10.2010 Transduction with old mVenus Stocks for taking pictures


    The motivation We transduced HT1080 with our stocks packaged with CMV_mVenus.
    The plan

    Days 22.9 23.9 24.9 25.9
    Action seeding HT1080 Transduction - Fluorescence microscopy

    The results

    Transduction with vectors pSB1C3_001_RC_IRCK_P5tataless as R/C and CMV_mVenus
    Freiburg10 transduction CMV mVenus 1.png
    Freiburg10 transduction CMV mVenus 2.png
    Freiburg10 transduction CMV mVenus 4.png

    23.10 Testing the bystander effect of the cytosine deaminase


    The motivation

    The activated form of 5-fluorocytosine has the ability to diffuse through the plasma membrane. In this way cells get killed which were not transduced by the viral particles. We use an old yfp stock t determine if the transgene expression is on and to harvest the cells which are transduced with cytosine deaminase loaded AAV2.

    The plan

    Days 23.10 24.10 25.10 26.10 27.10 28.10
    Action Transduce HT1080 and seed HT1080 Transfer the transduced HT1080 onto the non transduced HT1080 - - - Measure living cells via Neubauer cellchamber



    Gene of interest: CMV_Cytosindeaminase

    • P712

    Gene of interest: CMV_mVenus

    • P468


    All dishes had this order:

    1 2 3
    A Medium with prodrug Medium with prodrug Medium with prodrug
    B Medium Medium Medium


    The concentration of the prodrug 5-fluorocytosine is 54 mmolar

    Cells were seeded following this scheme:
    plate 1

    1 2 3
    A 1*105 HT1080 transduced with CMV_Cytosindeaminase 1*105 HT1080 transduced with CMV_Cytosindeaminase 1*105 HT1080 transduced with CMV_Cytosindeaminase
    B 1*105 HT1080 transduced with CMV_Cytosindeaminase 1*105 HT1080 transduced with CMV_Cytosindeaminase 1*105 HT1080 transduced with CMV_Cytosindeaminase



    plate 2

    1 2 3
    A 2*105 HT1080 non transduced 2*105 HT1080 non transduced 2*105 HT1080 non transduced
    B 2*105 HT1080 non transduced 2*105 HT1080 non transduced 2*105 HT1080 non transduced


    The next plates were seeded with non transduced cells and 1*105 of the cytosin deaminase transduced cells
    plate 3

    1 2 3
    A 2*105 HT1080 2*105 HT1080 2*105 HT1080
    B 2*105 HT1080 2*105 HT1080 2*105 HT1080

    The results

    25.10.2010 Transduction with several constructs for Flow Cytometry


    The motivation We want to quantify via flow cytometry the Affibody superconstruct, Darpin HSPG-KO Construct and standard R/C with HSPG-KO.
    The plan

    Days 25 26 27
    Action Transduction - FACS

    The results

    BLANK EXPERIMENT


    The motivation
    The plan

    Days - - - - - - - - -
    Action seeding AAV293 - Transfection - - Seeding HT Harvest + Transduction - FACS

    The results


    Citations


    [1] Media:Freiburg10_Stratagene_AAV_helper_free_manual.pdf
    [2] [http://www.copewithcytokines.de/cope.cgi?key=A431 Titel einfügen]
    [3] Read, A. P.; Strachan, T. (1999). "Chapter 18: Cancer Genetics". Human molecular genetics 2. New York: Wiley. ISBN 0-471-33061-2.
    [4] [http://www.biomol.de/dateien/infos_nr778.gif Titel einfügen]
    [5] Media:Freiburg10 Titration of AAV-2 particles via a novel capsid ELISA.pdf

    • Retrieved from "http://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal/Cellculture"